Enzyme based compositions and methods for removing dental calculi

HK40137508APending Publication Date: 2026-09-11PONTIS BIOLOGICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026126948
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-05
Filing Date
2026-08-03
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Compositions and formulations for removing dental calculi are disclosed comprising an enzyme or other biocatalyst that cleaves (i) a surface accessible nucleic acid polymer and (ii) a glycoprotein carbohydrate chain at galactose residues. Optionally, one or more proteolytic enzymes are included. The composition disrupts the structural integrity of the stone so that it is easy to remove without the need for special treatment by a training primordial dental professional. Also disclosed are methods for removing dental calculi using the disclosed compositions and formulations.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480013024.2 (22) Application Date 2024.01.05 (30) Priority Data 63 / 478641 2023.01.05 US (85) PCT International Application Entering National Phase Date 2025.08.15 (86) PCT International Application Application Data PCT / US2024 / 010512 2024.01.05 (87) PCT International Application Publication Data WO2024 / 148282 EN 2024.07.11 (71) Applicant Pontis Biotechnology Co., Ltd. Address New York, USA (72) Inventor D.C. Minalczyk (74) Patent Agency China Patent Agency (Hong Kong) Ltd. 72001 Patent Attorney Yue Xinchen Peng Chang (51) Int.Cl. A61K 8 / 66 (2006.01) A61Q 11 / 00 (2006.01) (54) Invention Title Enzyme-Based Compositions and Methods for Removing Dental Calculus (57) Abstract Compositions and formulations for removing dental calculus are disclosed, comprising an enzyme or other biocatalyst that cuts (i) surface-accessible nucleic acid polymers and (ii) glycoprotein carbohydrate chains at galactose residues. Optionally, one or more proteolytic enzymes are included. The composition disrupts the structural integrity of the calculus, making it easy to remove without special treatment by a trained dental professional. A method for removing dental calculus using the disclosed compositions and formulations is also disclosed. Claims (2 pages), Description (35 pages), Sequence Listing (electronic publication), Drawings (9 pages), CN 121463944 A 2026.02.03 CN 1 21 46 39 44 A 1. A dental composition comprising: a. a DNase and / or RNase; b. chymotrypsin or a functional variant or derivative thereof; and c. an orally acceptable additive, carrier, or excipient, or any combination thereof. 2. The dental composition according to claim 1, wherein the composition does not contain β-galactosidase. 3. The dental composition according to any one of claims 1 or 2, wherein the DNase is present in an amount of about 50,000 to about 250,000, or about 100,000 to about 200,000, or about 150,000 to about 200,000, or 150,000, or 160,000, or 170,000, or 180,000, or 185,000, or 190,000, or 200,000 Kunitz units / mL.4. The dental composition according to any one of claims 1-3, wherein the DNase is DNase I or a functional variant or derivative thereof. 5. The dental composition according to any one of claims 1-4, wherein chymotrypsin or a functional variant or derivative thereof is present in an amount of about 100 to about 5,000, or about 500 to about 4,000, or about 1,000 to about 3,000, or 1,500, or 1,600, or 1,700, or 1,800, or 1,900, or 2,000, or 2,100, or 2,200, or 2,300, or 2,400, or 2,500, or 2,600, or 2,700, or 2,800, or 2,900 or 3,000 units / mL based on the hydrolysis rate of the chromogenic substrate. 6. The dental composition of claim 1, wherein the orally acceptable additive is a thickener and / or gelling agent selected from gellan gum (low-acyl or high-acyl), glycerin, silica, guar gum, xanthan gum, polyethylene glycol, polyvinylpyrrolidone and its copolymers, polylactic acid, polyglycolic acid, long-chain fatty acid alcohols, cellulose-based polymers, acrylate polymers, and any combination thereof. 7. The dental composition of claim 1, wherein the orally acceptable carrier is selected from ethanol, isopropanol, glycerin, or sorbitol. 8. The dental composition of claim 1, further comprising a surfactant selected from cetearyl alcohol polyether or stearyl alcohol polyether. 9. The dental composition of claim 1, wherein the composition comprises: a. DNase I or a functional variant or derivative thereof; a. chymotrypsin or a functional variant or derivative thereof; and one or more of the following: c. 10%-20% glycerol; d. 0.000001%-0.00001% cetearyl alcohol polyether-25; e. 0.1%-0.5% xanthan gum; f. 1%-10% sorbitol; and g. 5-25% silica. 10. The dental composition of claim 9, further comprising water. 11. An oral hygiene device comprising the composition of any one of claims 1-10, wherein the composition is combined with a dental tray, capsule applicator, oral cleaning stick, or dental floss. 12. Use of the composition or device of any one of claims 1-11 for the removal of dental calculus in a subject in need of it. 13. Use of the composition of claim 12, wherein the subject is a mammal. 14. Use of the composition of claim 12, wherein the subject is a human.Claims 1 / 2 Page 2 CN 121463944 A 15. A method for reducing or removing dental calculus in a subject who requires it, the method comprising contacting a tooth surface with an effective amount of a composition comprising: a. DNase I or a functional variant or derivative thereof, and b. chymotrypsin or a functional variant or derivative thereof. 16. The method of claim 15, wherein the composition does not contain β-galactosidase. 17. The method of claim 15, wherein the composition further comprises an orally acceptable additive, carrier, or excipient, or a combination thereof. 18. The method of any one of claims 15-17, wherein the composition comprises a paste or liquid, and contacting the tooth surface comprises applying the composition using a brush, a tray, a mouthwash, or any combination thereof. 19. The method of claim 18, wherein the method comprises application at least once daily, at least twice daily, or at least three times daily for a period of at least one week. 20. A method for reducing or removing dental calculus in a subject who requires it, the method comprising contacting a tooth surface with an effective amount of a composition of any one of claims 1-10. 21. The method of any one of claims 15-20, wherein the subject is a mammal. 22. The method of claim 21, wherein the subject is a dog, horse, cat, or primate. 23. The method of claim 21, wherein the subject is a human. 24. A kit comprising: a. the composition of any one of claims 1-10; b. instructions for use. 25. The kit of claim 24, further comprising at least one applicator selected from toothbrushes, oral cleaning sticks, dental floss, and dental trays. Claims 2 / 2 Page 3 CN 121463944 A Enzyme-based Compositions and Methods for Removing Dental Calculus

[0001] Cross-Reference to Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 63 / 478,641, filed January 5, 2023, entitled “Enzyme-based Compositions and Methods for Removing Dental Calculus,” the contents of which are hereby incorporated by reference in their entirety. Technical Field

[0002] This disclosure relates to compositions and methods for reducing and removing dental plaque and calculus in humans and non-human animals.

[0003] Incorporation of Sequence Listing This application contains a sequence listing that has been filed by the Patent Center in .XML format and is hereby incorporated by reference in its entirety.The WIPO sequence list was created on January 4, 2024, named “119879-783212 Sequence Listing.xml”, and is 8 kilobytes in size. Background Art

[0004] Tartar, also known as dental calculus, is a petrified / mineralized substance that, if not removed, gradually accumulates and eventually leads to periodontal diseases such as gingivitis and periodontitis, resulting in a chronic inflammatory state that can induce diabetes or heart disease in humans and non-human animals (including but not limited to dogs and cats). Currently, tartar removal is performed by trained dental professionals, preferably once or twice a year, and is essentially limited to scraping the tooth surface with metal alloy dental probes or ultrasonic devices to break and remove the tartar from the enamel. Dental cleaning agents such as toothpaste and mouthwash used in routine daily oral hygiene practices are not effective at removing tartar.

[0005] The World Health Organization estimates that oral diseases affect nearly 3.5 billion people globally, with untreated dental caries being the most common health condition, and 1 billion people suffering from severe periodontal disease. The estimated number of cases of oral diseases globally exceeds the combined total of mental disorders, cardiovascular diseases, diabetes, chronic respiratory diseases, and cancer by approximately one billion. Furthermore, it is the most prevalent health problem in high-income countries. In the United States, data from the 2018 NHANES estimates that 42% of American adults with teeth have periodontitis and over 25% have untreated cavities. However, oral health problems extend beyond the oral cavity to systemic manifestations such as diabetes, cardiovascular disease, and premature infants with low birth weight. This link is not precisely defined but is generally associated with chronic inflammatory states stemming from periodontal inflammation. Oral biofilms are a major cause of various oral diseases, such as dental caries and periodontal disease. A key characteristic of biofilms, including dental plaque, is extracellular DNA (eDNA), which contributes to the gel-like properties of plaque formation. Bacteria living in dental biofilms are a major cause of periodontal disease. Additionally, bacterial species living in dental biofilms also metabolize sugars and produce acids, which lower the pH of the biofilm fluid. This leads to a mineral difference between the acidic biofilm fluid and the teeth, resulting in a loss of tooth mineral composition, clinically manifested as loss of tooth structure and cavitation. Controlling and preventing the accumulation of dental biofilm, plaque, and tartar is the goal of a healthy oral environment.

[0006] Oral hygiene, especially brushing, is a basic and daily habit for almost everyone, even in developing countries, and its purpose is to remove dental plaque. However, more than 40% of plaque will not be removed, even by trained individuals, and may become mineralized to become tartar. Current toothpastes are not very effective in preventing tartar formation but rather in reducing the rate of tartar formation.Specification 1 / 35 pages 4 CN 121463944 A

[0007] Therefore, there is a critical unmet need for products for routine home use that will reduce, remove and / or prevent dental calculus. Summary of the Invention

[0008] In various aspects of this disclosure, there is a first dental composition comprising or substantially consisting of at least two calculus-targeting enzymes. Other aspects and features of this disclosure are detailed below.

[0009] In one aspect, this disclosure includes a dental composition comprising a DNase, a chymotrypsin or a functional variant or derivative thereof, and an orally acceptable additive, carrier or excipient or any combination thereof. In some aspects, the dental composition is a dental cleaning agent.

[0010] In some aspects, the dental composition may not include β-galactosidase.

[0011] In some aspects, the dental composition may include an amount of DNase in the form of about 50,000 to about 250,000, or about 100,000 to about 200,000, or about 150,000 to about 200,000, or 150,000, or 160,000, or 170,000, or 180,000, or 185,000, or 190,000, or 200,000 Kunitz units / mL.

[0012] In some aspects, the dental composition may also include a DNase, wherein the DNase is DNase I or a functional variant or derivative thereof.

[0013] In some aspects, the dental composition may also include chymotrypsin or a functional variant or derivative thereof, wherein the chymotrypsin or functional variant or derivative is present in an amount of about 100 to about 5,000, or about 500 to about 4,000, or about 1,000 to about 3,000, or 1,500, or 1,600, or 1,700, or 1,800, or 1,900, or 2,000, or 2,100, or 2,200, or 2,300, or 2,400, or 2,500, or 2,600, or 2,700, or 2,800, or 2,900 or 3,000 units / mL.

[0014] In some aspects, the dental composition may further include oral-acceptable additives, wherein the oral-acceptable additives are thickeners and / or gelling agents selected from gellan gum (low-acyl or high-acyl), glycerin, silica, guar gum, xanthan gum, polyethylene glycol, polyvinylpyrrolidone and copolymers thereof, polylactic acid, polyglycolic acid, long-chain fatty acid alcohols, cellulose-based polymers, acrylate polymers, and any combination thereof. In some aspects, the dental composition is a dental cleaning agent.

[0015] In some aspects, the dental composition may further include oral-acceptable carriers, such as ethanol, isopropanol, glycerin, sorbitol, or any combination thereof.

[0016] In some aspects, the dental composition may further include surfactants, such as cetearyl alcohol polyether or stearyl alcohol polyether.

[0017] In some aspects, the dental composition comprises DNase 1 or a functional variant or derivative thereof, chymotrypsin or a functional variant or derivative thereof, and one or more of 10-20% glycerol, 0.00001-0.000001% cetearyl alcohol polyether-25, 0.1%-0.5% xanthan gum, 1-10% sorbitol, and 5-25% silica. The composition may further comprise water.

[0018] In some aspects, the dental composition is in the form of a paste or gel, such as toothpaste or dental floss, or tooth powder, or mouthwash. In some aspects, the dental composition is a dental floss. In some aspects, the dental composition is combined with a dental tray, capsule applicator, oral pick, or dental floss to provide an oral hygiene device.

[0019] In some aspects, this disclosure also includes the use of the dental composition or a device comprising the dental composition for the removal of tartar in a subject in need of it. In some aspects, the dental composition is used as a dental floss. In some aspects, the subject is a mammal. In some aspects, the subjects are humans.

[0020] In some aspects, this disclosure provides a method for reducing or removing dental calculus in subjects in need of it. The method includes contacting a tooth surface with an effective amount of a dental composition comprising DNase I or a functional variant or derivative thereof, and chymotrypsin or a functional variant or derivative thereof. In some aspects, the dental composition is formulated as a dental flosser.

[0021] In some aspects, the dental composition does not contain β-galactosidase.

[0022] In some aspects, the composition further comprises an orally acceptable additive, carrier, or excipient, or a combination thereof.

[0023] In some aspects, the composition comprises a paste or liquid and contact with the tooth surface comprises applying the composition using a brush, a tray, a mouthwash, or any combination thereof. In some aspects, the dental composition is formulated as a dental flosser.

[0024] The method may further include the method comprising application at least once a day, at least twice a day, or at least three times a day for a period of time of at least one day, one week, one month, or one year or longer.

[0025] In some aspects, this disclosure provides a method for reducing or removing tartar in a subject in need of it, wherein the method comprises contacting a tooth surface with an effective amount of a dental composition (e.g., a dental cleaning agent).

[0026] In some aspects, the subject is a mammal. In some aspects, the subject is a dog, horse, cat, or primate. In some aspects, the subject is a human.

[0027] In some aspects, this disclosure also includes a kit comprising a dental composition and instructions for use. In some aspects, the kit contains the dental composition as a dental cleaning agent.The kit may further include at least one applicator selected from toothbrushes, oral cleaning sticks, dental floss, and dental trays.

[0028] Other technical features are readily apparent to those skilled in the art from the following figures, description, and claims. Brief Description of the Drawings

[0029] Aspects of this disclosure are illustrated in the following figures: Figure 1 is a schematic diagram of a proof-of-concept in vivo study design. A randomized trial was conducted to evaluate the safety and efficacy of an exemplary formulation for removing existing calculus deposits over a 4-week trial period.

[0030] Figure 2 provides an overview of the scoring associated with the Volpe-Manhold index. The score is based on the cumulative calculus score, which is the sum of the lingual (tongue-facing) surfaces of the 6 lower anterior (incisor) teeth.

[0031] Figure 3 shows that the formulation significantly reduced total tartar as estimated by the Volpe-Manhold score.

[0032] Figure 4 shows the change in tartar percentage in all subjects of the trial. The change in tartar was consistent across all subjects; tartar increased in all patients except 2 control patients, and decreased in all subjects except 1 subject.

[0033] Figure 5 shows the positive response of subjects to the disclosed formulation.

[0034] Figure 6 depicts an overview of the daily brushing schedule of the study group.

[0035] Figure 7 shows the individual V-MI values ​​of different treatment groups at baseline and 4 weeks.

[0036] Figure 8 shows the percentage of patients who gave a favorable score ("4" or "5" on a 5-point scale) for how clean their teeth felt. The score is rated on a 5-point scale, where "1" is the least clean you can imagine and "5" is the cleanest you can imagine. Detailed Description

[0037] This disclosure provides novel dental compositions and formulations for reducing or removing tartar in humans and non-human animals (including, but not limited to, dogs and cats), methods for reducing or removing tartar, and kits containing the compositions and formulations.

[0038] Definitions 3 / 35 pages 6 CN 121463944 A Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this disclosure pertains.The following references provide general definitions of many terms used in this disclosure to those skilled in the art: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd edition, 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th edition, R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, unless otherwise stated, the following terms have the meanings assigned to them.

[0039] When introducing elements of this disclosure or preferred embodiments thereof, the articles “a,” “an,” “the,” and “said” are intended to mean the presence of one or more elements. The terms “comprising,” “including,” and “having” are intended to be inclusive and mean that additional elements besides those listed may be present.

[0040] A range may be expressed herein as from “about” a particular value and / or to “about” another particular value. When such a range is expressed, another embodiment includes from one particular value and / or to another particular value. Similarly, when a value is expressed as an approximation using the antecedent “about”, it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each range are significant both relative to and independent of the other endpoint. It is also understood that there are many values ​​disclosed herein, and each value, in addition to itself, is also disclosed herein as “about” that particular value. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that when a value is disclosed, “less than or equal to” that value, “greater than or equal to” that value, and possible ranges between the values ​​are also disclosed, as properly understood by one of the skill in the art. For example, if the value “10” is disclosed, then “less than or equal to 10” and “greater than or equal to 10” are also disclosed. It is also understood that throughout the application, data is provided in many different formats, and that the data represents a range of endpoints and starting points, as well as any combination of data points. For example, if specific data point "10" and specific data point 15 are disclosed, it should be understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15, as well as those between 10 and 15, are disclosed. It is also understood that each unit between two specific units is also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0041] As used herein, the terms “optional” or “optionally” mean that the events or conditions described below may or may not occur, and the description includes both the cases in which said events or conditions occur and the cases in which they do not occur.

[0042] As used herein, the terms “calculus” or “tartar” are used interchangeably and refer to a form of hardened dental plaque. It is caused by the deposition of minerals from saliva and gingival crevicular fluid in plaque on the teeth. This deposition process kills bacterial cells within the plaque, but the resulting rough and hardened surface provides an ideal surface for further plaque formation. This leads to calculus buildup, which can impair the health of the gums (dental gingiva). Calculus can form along the gingival line (where it is called supragingival) and within the narrow gingival sulcus that exists between the teeth and the gums (where it is called subgingival).

[0043] As used herein, the term “stone-targeting enzyme” means any of the following: (i) an enzyme that hydrolyzes the sugar-phosphate bonds of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA); (ii) a proteolytic enzyme that hydrolyzes amino acid linkages in a protein backbone; and optionally (iii) an enzyme that hydrolyzes glycoprotein carbohydrates at linkages containing galactose, N-acetyl-glucosamine, fucose, N-acetyl-galactosamine, or sialic acid. Stone-targeting enzymes include, but are not limited to, DNases, chymotrypsin, and other proteases, including, but not limited to, the specific enzymes disclosed elsewhere herein. In all respects, stone-targeting enzymes are not β-galactosidases, i.e., compositions as disclosed herein specifically exclude β-galactosidases.

[0044] As used interchangeably herein, the terms “polypeptide” and “protein” refer to polymers of amino acids of any length. Polymers may be linear or branched, may contain modified amino acids, and may be non-amino acid-discontinuous. These terms also include amino acid polymers, whether naturally occurring or modified by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeled component. The definition also includes, for example, polypeptides containing one or more amino acid analogs (including, for example, non-natural amino acids), and other modifications known in the art. For example, as used herein, the protein or polypeptide sequence of an enzyme (as a non-limiting example, DNase I (also known as DNase I)) or chymotrypsin also includes derivatives and variants of the polypeptide, as modified as provided herein.

[0045] The terms “derivative” or “variant,” when used herein for a polypeptide, refer to a polypeptide that is associated with the wild-type polypeptide, for example, by its amino acid sequence, structure (e.g., secondary and / or tertiary), activity (e.g., enzyme activity), and / or function.Compared to the wild-type polypeptide, derivatives or variants of the polypeptide may contain one or more amino acid changes (e.g., mutations, insertions, and deletions), truncations, modifications, or combinations thereof. As used herein, the term "functional variant or derivative" includes proteins that have the same or enhanced or reduced functional levels compared to their wild-type polypeptide.

[0046] Throughout this specification, unless the context otherwise requires, the words "comprise" and "include" and their variants (e.g., "comprises", "comprising", "includes", "including") will be understood to mean including the stated component, feature, element, or step, or a group of components, features, elements, or steps, but without excluding any other integer or step, or a group of integers or steps.

[0047] As used herein, "and / or" should be understood to specifically disclose each of the two specified features or components, and or not with the other. For example, “A and / or B” should be considered as a specific disclosure of each of (i) A, (ii) B, and (iii) A and B, as if each were listed separately herein.

[0048] Furthermore, this disclosure also contemplates the exclusion or omission of any feature or combination of features set forth herein in some embodiments. For illustration, if the specification states that a complex comprises components A, B, and C, it is specifically intended that any one or any combination of A, B, or C may be omitted or denied individually or in any combination.

[0049] Unless otherwise stated herein, the enumeration of value ranges herein is intended only as a method of abbreviating each individual value falling within that range, and each individual value is incorporated into the specification as if it were listed separately herein. For example, if the concentration range is stated as 1%–50%, it is intended that values ​​such as 2%–40%, 10%–30%, or 1%–3% are explicitly enumerated herein. These are merely examples of what is specifically expected, and it is believed that all possible combinations of values ​​between (including) the listed minimum and maximum values ​​are explicitly stated in this disclosure.

[0050] As used herein, “individual,” “subject,” “host,” and “patient” are used interchangeably herein and refer to any mammalian subject for diagnosis, treatment, prevention, or therapy, such as a human, pet, livestock, horse, or other animal. As used herein, the terms “subject” and “patient” are used interchangeably herein and refer to both human and non-human animals. The term “non-human animal” in this disclosure includes all vertebrates, such as mammals and non-mammals, such as non-human primates, dogs, cats, etc. In some aspects, the subject may be a human.

[0051] As used herein, the terms “administer,” “administering,” or “administration” mean the oral administration of a compound or composition, regardless of its form. For example, the methods disclosed herein include administering an effective amount of a compound or composition to achieve a desired or stated effect. The compositions disclosed herein may optionally be administered to the oral cavity or a specific part of the oral cavity (e.g., a brush, toothbrush), floss or dental flosser (e.g., dental floss), irrigator (e.g., a water flosser), cleaning stick (e.g., a dental probe or toothpick), scraper (e.g., a tongue cleaner or tongue scraper), spatula, rod, retainer, mouthguard, etc., using one or more devices known in the art, such as a brush (e.g., a toothbrush), floss or dental flosser (e.g., dental floss), a water flosser (e.g., a water flosser), a cleaning stick (e.g., a dental probe or toothpick), a scraper (e.g., a tongue cleaner or tongue scraper), a spatula, a stick, a retainer, a mouthguard, etc.).

[0052] As used herein, the terms “treat,” “treating,” or “treatment” mean the partial or complete relief, suppression, improvement, or reduction of a disease or condition suffered by a subject. This means any way in which one or more symptoms (e.g., calculus) of the disease or disorder described in page 5 / 35 of CN 121463944 A can be improved or otherwise beneficially altered. As used herein, improvement of symptoms of a particular disorder (e.g., calculus) means any relief, whether permanent or temporary, persistent or transient, that can be attributed to or related to treatment by the compositions and methods of this disclosure. In some aspects, treatment may promote or result in, for example, a reduction in the amount of calculus (e.g., in the subject) relative to the amount of calculus before treatment; or a reduction in one or more symptoms in the subject associated with one or more periodontal diseases (e.g., gingivitis) relative to the symptoms in the subject before treatment.

[0053] As used herein, the terms “prevent,” “preventing,” and “prevention” mean a reduction in the occurrence of disease or a reduction in the risk of disease or its associated symptoms in the subject. Prevention may be complete, for example, the complete absence of disease in the subject. Prevention may also be partial, such that the disease in the subject is less, occurs later, or develops more slowly than would occur without this disclosure.

[0054] Since various changes can be made to the above-described units and methods without departing from the scope of consideration of this disclosure, it is contemplated that all things contained in the above description and the examples given below should be interpreted in an illustrative rather than limiting sense.

[0055] (I) Dental calculus Calculus has a complex composition and will vary between individuals depending on diet, genetics (subtle compositional variations in saliva) and the composition of the oral microbiome, but the mechanism of its deposition remains to be determined.In a recent report (Aghanashini, S. et al., J. of Health Sciences and Res. (2016) 7:42-50), six theories of calculus formation were reviewed: the Booster mechanism; the Epitactic concept; the inhibition theory; the conversion theory; the bacterial theory; and the enzymatic theory. All theories except the bacterial theory focus on inorganic components. The bacterial theory assumes that bacteria attached to the tooth surface are the cause of calculus formation. Research from the United States in the 1960s and 1970s focused on the composition of calculus hydrolysis products and did not venture to identify macromolecular organic components (if any). Since then, no further progress has been made in the United States. Therefore, the field has not consolidated around a single view on calculus development.

[0056] Recent studies of dental calculus collected from ancient teeth have evaluated the presence of DNA and shown that DNA is an extremely robust molecule. DNA is negatively charged, and in addition to DNA, calculus also contains salivary glycoproteins, among which mucins are the most abundant members of the negatively charged group. Calcium is positively charged and abundant in saliva, mediating salt bridges between negatively charged DNA and mucins. Another component of calculus formation is the protein network structure generated by transglutaminase activity, which crosslinks glutamine residues on a protein with lysine residues on adjacent protein molecules. This process is thought to originate at the tooth / gingival interface, where surface proteins on the epithelial surface become crosslinked with soluble salivary proteins, creating a network structure extending from the epithelium to the enamel surface. Thus, at the tooth / gingival interface, proteins on the epithelial surface are crosslinked with other salivary and food proteins by transglutaminase, thereby generating additional base material for mineralization.

[0057] The model disclosed herein begins with chemically cleaned tooth enamel in a normal oral environment. Unexpectedly bound by theory, it is thought that DNA and mucin will bind to positively charged calcium ions on the outer surface of enamel hydroxyapatite (Ca10(PO4)6(OH)2), and salivary calcium will further associate with the outer surface of enamel-associated DNA and mucin, initiating lamination by attracting more calcium, DNA, and mucin. It is further thought that less abundant but much larger DNA from the oral environment will associate with available hydroxyapatite calcium and with calcium bound to the outer surface of immobilized mucin. DNA and mucin can be approximated as cylindrical structures with charged groups arranged radially. Therefore, only a small fraction of the charged groups will occupy the molecular surface interacting with the underlying matrix (1 / 4–5 in the case of DNA). Thus, the effectiveness of the cooperative interaction depends on molecular length to provide the strength required for the interaction to have sufficient duration in a highly hydrated environment.The strength of the cooperating interaction is reduced by decreasing the length of the DNA polymer or by cleaving the negatively charged protein and / or carbohydrate chains terminated on the glycoprotein peptide backbone. As the length of the negatively charged polymer decreases due to DNA cleavage, and the cleavage of the glycoprotein chains from the glycoprotein peptide backbone increases, the cooperating interaction essential to the structure of stones and plaques is lost, allowing the components to be flushed away.

[0058] DNA is generally considered to be highly resistant to cleavage. Chemical hydrolysis of DNA requires boiling it in acid. The relationship of DNA length relative to bacterial cells is on a macroscopic scale, but the role of DNA and glycoproteins such as mucins in plaque and stone formation is on a molecular scale. The number of association events that can be achieved between mucins and DNA is enormous, which contributes to the strength of stone aggregates. Therefore, the extensive length and chemical impermeability of DNA make it a strategic component of stones. Although glycoproteins are not as robust as DNA, they are strong enough to play an important structural role. The association of both glycoproteins and DNA with immobilized calcium is enhanced through cooperation. In this case, synergy is like the base pairing of double-stranded DNA. Although DNA base pair interactions are established by hydrogen bonding (weak, compared to the dominant ionic salt bridges in calculi), the precise geometry of the double helix and the large number of base pairs make separating the two strands difficult enough that near-boiling temperatures are required. In the case of calculi formation, when one salt bridge loosens through competition with water, those remaining upstream and downstream salt bridges will keep the two loosened bridge partners close enough to promote their rapid reassociation.

[0059] Purely chemical methods for removing calculi require chemically extreme, oral-damaging chemical environments. However, biological / enzymatic methods would be nontoxic, efficient, and effective for disintegrating dental calculi. DNA can be cleaved at accessible sugar-phosphate bonds anywhere along its length by deoxyribonucleases (DNases), which reduces the length of the DNA polymer to short DNA fragments (oligonucleotides) with a proportional loss of synergy. The elements of the mucin glycoprotein that associates with calcium are the sulfate and sialic acid groups at the ends of the carbohydrate chains (both are negatively charged). The carbohydrate chains of sialic mucins are diverse and large. They terminate with neutral sugars (56%), sialic acid (26%), and sulfates (19%), with average chain lengths of 13, 17, and 41 units, respectively (Thomsson, KA, Glycobiology (2002) 12: 1–14). The carbohydrate chains are mainly composed of galactose, fucose, and N-acetylglucosamine, with a smaller amount of N-acetylglucosamine. Mucin glycoproteins dimerize end-to-end and then continue to form higher-order structures.The microbes of the oral and gut microbiome have evolved to utilize mucinous carbohydrates as a nutrient source. They secrete N-acetyl-glucosaminease, β-galactosidase, N-acetyl-galactosidase, fucosidase, and neuraminidase (sialic acidase) to cleave carbohydrate chains into smaller sizes for nutrient absorption (Derrien, M., Gut Microbes (2010) 1:254-268). Although the most accessible regions for cleaving carbohydrate chains with β-D-galactosidase and β-N-acetyl-D-glucosaminease are at the galactose and N-acetyl-glucosamine residues in the middle of the chain, any cleavage that removes acidic sulfate and sialic acid units from the protein chain will eliminate the synergy, which is important in stone and plaque structures.

[0060] During the formation of DNA / mucin / calcium complexes, they mix with other salivary proteins and proteins from the diet, which are continuously cross-linked by transglutaminase. Over time, more calcium diffuses into the aggregates, further compacting the stone as it mineralizes. This underscores the effectiveness of additional enzymes (e.g., chymotrypsin) that target the polypeptide components of these glycoproteins, as also found herein, in enhancing the breakdown of stone and plaque structures.

[0061] Stones are solid, thus exposing only their two-dimensional surface to the environment. Therefore, a single enzyme, such as DNase activity, is limited to digesting surface-accessible DNA. It cannot reach DNA buried beneath the exposed layer of cross-linked proteins. The same is true if only proteases, such as chymotrypsin activity, are used. They digest the surface-exposed cross-linked protein network until what remains of the surface-exposed layer is a completely protease-impenetrable salt-bridged DNA / mucin layer. This requires the combined use of enzymes to gradually attack the stone surface.

[0062] (II) Dental Compositions and Formulations The compositions and formulations according to this disclosure comprise at least two stone-targeting enzymes and may comprise combinations of two or more stone-targeting enzymes, each enzyme having different catalytic activities that hydrolyze different chemical components in the stone structure. Targeting enzymes for calculi include enzymes that hydrolyze any of the following: (i) sugar-phosphate bonds of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA); (ii) proteins, including glycoproteins; and (iii) glycoprotein carbohydrates. Targeting enzymes for calculi, including DNases, RNases, and proteases, act on readily accessible nucleic acid and glycoprotein elements on the surface of dental plaque and calculi. For example, when surface-accessible DNA is cleaved into shorter fragments by a DNase, the shorter fragments lose their ability to co-associate with the underlying matrix, thereby allowing water to displace the cleaved DNA and proteins.Similarly, when surface-accessible glycoprotein carbohydrate chains are cleaved by β-galactosidase, for example, the underlying sialic acid / sulfate-calcium associations become singular, i.e., no longer attached to the protein backbone, nor part of the cooperating structure, and are effectively replaced by a large amount of water. However, unexpectedly, this function can also be provided by the presence of proteases that carry out proteolysis and promote glycoprotein degradation, thereby abandoning the need for β-galactosidase. When surface-accessible nucleic acids and glycoproteins are cleaved and replaced, the nucleic acids and glycoproteins below the replaced cleaved nucleic acids and glycoproteins are now accessible by DNases or RNases and protein-cleaving enzymes, which repeat the progressive cycle of cleavage and replacement, thereby disintegrating the three-dimensional plaque and calculus structure, thereby disintegrating plaque and calculus.

[0063] Thus, in one aspect, the dental composition according to the present disclosure comprises at least two enzymes targeting calculus: a first enzyme selected from those having catalytic activity of hydrolyzing phosphate ester bonds in nucleic acids including DNA and RNA, or other biocatalysts; and a second enzyme or other biocatalyst having catalytic activity of hydrolyzing proteins, or any combination thereof. In each aspect, the enzyme that hydrolyzes proteins is chymotrypsin or a functional variant or derivative thereof.

[0064] In the disclosed compositions, at least one stone-targeting enzyme or other biocatalyst may be a DNase and / or RNase having catalytic activity of hydrolyzing phosphate ester bonds in DNA and RNA. In one aspect, at least one stone-targeting enzyme is a DNase, such as DNase I. In another aspect, at least one stone-targeting enzyme is an RNase. In yet another aspect, at least one stone-targeting enzyme is a nuclease that is both a DNase and an RNase, such as NuCLEANase food grade (commercially available from c-LEcta GmbH of Leipzig, Germany).

[0065] The amount of nuclease (DNase and / or RNase) may vary from about 50,000 Kunitz units / mL to about 800,000 Kunitz units / mL. For example, in various aspects, the nuclease is present in the composition in amounts of about 100,000 Kunitz units / mL, about 200,000 Kunitz units / mL, about 300,000 Kunitz units / mL, about 400,000 Kunitz units / mL, about 500,000 Kunitz units / mL, about 600,000 Kunitz units / mL, about 700,000 Kunitz units / mL, or about 750,000 Kunitz units / mL. In some aspects, the amount of nuclease may be from about 200 Kunitz units / mL to about 100,000 Kunitz units / mL.For example, in various aspects, the nuclease is present in the composition in amounts of about 200 Kunitz units / mL, about 300 Kunitz units / mL, about 400 Kunitz units / mL, about 500 Kunitz units / mL, about 600 Kunitz units / mL, about 700 Kunitz units / mL, about 800 Kunitz units / mL, about 900 Kunitz units / mL, about 1000 Kunitz units / mL, about 1500 Kunitz units / mL, about 2,000 Kunitz units / mL, about 2500 Kunitz units / mL, about 3000 Kunitz units / mL, about 4000 Kunitz units / mL, about 5000 Kunitz units / mL, about 6000 Kunitz units / mL, about 7000 Kunitz units / mL, about 8000 Kunitz units / mL, about 9000 Kunitz units / mL, or about 100,000 Kunitz units / mL.

[0066] In some aspects, nucleases from any suitable source organism may be used. In some aspects, the nuclease may be from a recombinant source. In some aspects, the nuclease may be synthetic. Non-limiting examples of DNases are bovine pancreatic deoxyribonuclease (i.e., "deoxyribonuclease I"; SEQ. ID. NO.: 1) or functional variants or derivatives thereof. In some aspects, the DNase comprises a polypeptide sequence having at least about 60% to about 75%, or about 75% to about 80%, or about 80% to about 85%, or about 85% to about 90%, or about 90% to about 95%, or about 95% to about 100% identity with SEQ ID NO: 1. In some aspects, the polypeptide has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with SEQ ID NO: 1.

[0067] In another aspect, the composition further comprises a protease, such as chymotrypsin.Chymotrypsin, also known as EC 3.4.21.1, chymotrypsin A and B, α-chymar ophth, avazyme, chymar, chymotest, enzeon, quimar, quimotrase, α-chymar, and α-chymotrypsin A, is a serine protease produced by the pancreas that hydrolyzes peptide bonds of tryptophan, leucine, tyrosine, and phenylalanine. Chymotrypsin preferably cleaves peptide amide bonds, wherein the N-terminal amino acid side chain (P1 position) of the readily cleaved amide bond is a large hydrophobic amino acid (tyrosine, tryptophan, and phenylalanine). These amino acids contain an aromatic ring in their side chain, which is inserted into the hydrophobic pocket of the enzyme (S1 position). Chymotrypsin also hydrolyzes other amide bonds in peptides at a slower rate, particularly those containing leucine and methionine at the P1 position.

[0068] Chymotrypsin is produced in vivo as an inactive precursor, chymotrypsinogen (e.g., bovine chymotrypsinogen, SEQ. ID. NO: 2). It is activated in its active form by another enzyme called trypsin. This active form is called π-chymotrypsin and is used to produce α-chymotrypsin. Trypsin cleaves the peptide bond between arginine-15 and isoleucine-16 in chymotrypsinogen. This produces two peptides within the π-chymotrypsin molecule, which are linked together by disulfide bonds. One of the π-chymotrypsins acts on the other by breaking the leucine and serine peptide bonds. The activated π-chymotrypsin reacts with other π-chymotrypsin molecules to cleave two dipeptides, namely serine-14-arginine-15 and threonine-147-asparagine-148. The reaction produces α-chymotrypsin, comprising chymotrypsin A, chymotrypsin B, and chymotrypsin C (SEQ ID NO: 3, 4, and 5, respectively), which are linked via disulfide bonds to form active α-chymotrypsin.

[0069] In some aspects, chymotrypsin from any suitable source organism can be used. In some aspects, the chymotrypsin may be from a recombinant source. In some aspects, the chymotrypsin may be synthetic. In some aspects, the composition comprises a polypeptide containing one or more of SEQ ID NO: 3, 4, or 5, or a variant or derivative thereof. In some aspects, the chymotrypsin is a recombinant chymotrypsin that has been optimized for commercial production or commercial use. In some aspects, the recombinant chymotrypsin is optimized for use in dental products.In some aspects, the composition comprises a polypeptide sequence having at least about 60% to about 75%, or about 75% to about 80%, or about 80% to about 85%, or about 85% to about 90%, or about 90% to about 95%, or about 95% to about 100% identity with one or more of SEQ ID NO: 3-5. In some aspects, the composition comprises a polypeptide having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with one or more of SEQ ID NO: 3-5.

[0070] In some aspects, the amount of chymotrypsin is present in functional units based on the hydrolysis rate of the chromogenic substrate, in an amount of about 100 to about 5,000, or about 500 to about 4,000, or about 1,000 to about 3,000, or 1,500, or 1,600, or 1,700, or 1,800, or 1,900, or 2,000, or 2,100, or 2,200, or 2,300, or 2,400, or 2,500, or 2,600, or 2,700, or 2,800, or 2,900 or 3,000 units / mL.

[0071] In some aspects, the dental composition may contain additional proteolytic enzymes. Non-limiting examples of proteolytic enzymes include aminopeptidase M, bromelain, carboxypeptidase A, carboxypeptidase B, carboxypeptidase Y, cathepsin C, chymotrypsin, collagenase, dispersin, endopeptidase Arg-C, endopeptidase Asp-N, endopeptidase Glu-C, endopeptidase Lys-C, enterokinase, factor Xa, figolytic enzyme, kallikrein, papain, pepsin, plasmin, streptomycin, proteinase K, subtilisin, thermophilic protease, thrombin, or trypsin.

[0072] In some aspects, the dental composition may further comprise a calculus-targeting enzyme that hydrolyzes carbohydrate polymers of glycoproteins. In all aspects, the calculus-targeting enzyme that hydrolyzes carbohydrate polymers of glycoproteins is not β-galactosidase. Specification 9 / 35 pages 12 CN 121463944 A

[0073] In some aspects, the dental compositions disclosed herein comprise an effective amount of a nuclease (DNase and / or RNase) and an effective amount of chymotrypsin or a functional variant or derivative thereof. In some aspects, the dental compositions disclosed herein comprise an effective amount of a DNase and an effective amount of chymotrypsin or a functional variant or derivative thereof. In some aspects, the dental compositions disclosed herein comprise an effective amount of DNase I and an effective amount of chymotrypsin or a functional variant or derivative thereof.In some aspects, the dental compositions disclosed herein comprise an effective amount of a nuclease (DNase and / or RNase), an effective amount of chymotrypsin or a functional variant or derivative thereof, an orally acceptable additive, carrier, or excipient, or any combination thereof. In some aspects, the dental compositions disclosed herein comprise an effective amount of a DNase, an effective amount of chymotrypsin or a functional variant or derivative thereof, an orally acceptable additive, carrier, or excipient, or any combination thereof. In some aspects, the dental compositions disclosed herein comprise an effective amount of DNase I, an effective amount of chymotrypsin or a functional variant or derivative thereof, an orally acceptable additive, carrier, or excipient, or any combination thereof.

[0074] In some aspects, the dental compositions disclosed herein do not contain β-galactosidase. In some aspects, the dental compositions consist essentially of an effective amount of a nuclease (DNase and / or RNase) and an effective amount of chymotrypsin or a functional variant or derivative thereof. In some aspects, the dental compositions consist essentially of an effective amount of a DNase and an effective amount of chymotrypsin or a functional variant or derivative thereof. In some aspects, the dental compositions consist essentially of an effective amount of DNase I and an effective amount of chymotrypsin or a functional variant or derivative thereof.

[0075] The units of enzymes disclosed herein should be understood according to the customary usage of each enzyme in the art. For example, for DNase, 1 unit is defined as the amount of enzyme required to produce an absorbance increase of 0.001 / min / mL at 260 nm by generating highly polymerized DNA at 25°C under conditions of HCl (pH 7.5), 50 mM MgCl2, and 13 mM CaCl2. For chymotrypsin, 1 unit is the amount of enzyme required to hydrolyze 1 μmol of N-benzoyl-L-tyrosine ethyl ester per minute at pH 7.8 and 25°C. For proteinase K, 1 unit is the amount of enzyme required to digest urea-denatured hemoglobin per minute at pH 7.5 and 37°C using Folin & Ciocalteu phenol reagent to produce an absorbance equivalent to 1.0 µmol of L-tyrosine (6). (See, for example, www.worthington-biochem.com / PROK / cat.html). Those skilled in the art will appreciate how to define units for other proteolytic enzymes. In the following examples, amylase and RNase without DNA enzyme are used as controls.

[0076] The stabilizing enzymes used to prepare dental compositions and formulations are readily available from commercial enzyme suppliers such as Worthington Biochemical Corp. (Lakewood, NJ) as purified lyophilized powders. The enzymes may be derived from animal tissues, such as animal (e.g., bovine) pancreas, or produced using recombinant methods. The lyophilized powder is dissolved in an aqueous solvent, which may be water.Add sufficient solvent to commercially available lyophilized powder vials to fill them approximately halfway, and fill the remaining portion with glycerin to produce a moderately stable 50 / 50 water / glycerin solution. This solution can be kept in a refrigerator for at least several weeks. Extract approximately 50 μl to approximately 200 μl of each enzyme solution using a plastic or glass pipette or other instrument. Then apply the enzyme or other biocatalyst solution, or a combination of enzyme or other biocatalyst solutions, or a composition or formulation containing an enzyme, to the teeth, paying particular attention to the gingival margin, using any of the various known oral application methods or tools. For example, the enzyme solution or a composition or formulation containing one or more enzymes can be applied to a toothbrush, or preferably a small interdental cleaning stick with a brush. Alternatively, multiple enzymes can be prepared as described and then combined in a single solution and then applied to an application brush, or each enzyme solution can be applied to the brush individually. Alternatively, a composition or formulation containing one or more enzymes can be prepared as described and then applied to an application brush. A brush is used to apply the enzyme solution to the tooth surface, paying particular attention to the gingival margin, where tartar tends to form.

[0077] As described above, any one or more tartar-targeting enzymes can be prepared as a simple solution or combined with orally acceptable additives, carriers, or excipients to prepare a liquid, paste, or gel form that helps maintain contact between the enzyme and the tooth surface for a longer period than is permitted by liquids. As disclosed herein, the enzyme solution can be combined with or added to mouthwash instructions (page 10 / 35, 13 CN 121463944 A) or toothpaste compositions as known in the art. Non-limiting examples of orally acceptable additives, carriers, or excipients are generally as known in the art and include thickeners or gelling agents, binders, stabilizers, preservatives, flavoring agents, fluoride salts, surfactants, abrasives, tartar control agents, calcium chelating agents, and colorants. Additives such as flavoring agents and colorants can be generally as known in the art and are readily commercially available.

[0078] Non-limiting examples of adhesives include carboxyvinyl polymers (such as polyacrylic acid crosslinked with polyallyl sucrose or polyallyl pentaerythritol), hydroxyethyl cellulose, hydroxypropyl cellulose, water-soluble salts of cellulose ethers (such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose), and natural gums (such as carrageenan, guilarin, guar gum, xanthan gum, gum arabic, and tragacanth gum).

[0079] Non-limiting examples of thickeners and gelling agents are gellan gum (low-acyl or high-acyl), glycerin, silica, guar gum, xanthan gum, polyethylene glycol, polyvinylpyrrolidone and its copolymers, polylactic acid, polyglycolic acid, long-chain fatty acid alcohols, cellulose-based polymers, and acrylate polymers.

[0080] Non-limiting examples of carriers are orally acceptable alcohols, such as ethanol, isopropanol, and glycerin.Non-limiting examples of plaque control agents are generally as known for commercially available dental cleaning products, such as pyrophosphates and their salts, polyphosphates, polyphosphonates and mixtures thereof. Pyrophosphates include dialkali metal and tetraalkali metal pyrophosphates and mixtures thereof. Non-limiting examples of antibacterial agents and preservatives are quaternary ammonium salts, their polymers, chlorhexidine and its salts, polyhexamethylene biguanide, oxytinidin, organic acids, chelating agents such as calcium chelating agents (e.g., ethylenediaminetetraacetic acid (EDTA)), essential oils, and parabens. Non-limiting examples of antibiotics are penicillin and tetracycline. Non-limiting examples of oral-acceptable abrasives are silica, including fumed silica, or other inorganic particles, synthetic polymer particles, or organic particles, such as plant-derived particles.

[0081] Any oral-acceptable surfactant can be used, most of which are anionic, nonionic, or amphoteric. In some respects, the choice and amount of surfactant are such that it does not interfere with enzyme activity. Non-limiting examples of nonionic surfactants include cetearyl alcohol polyether, stearyl alcohol polyether, polyethoxylated fatty acid sorbitan esters, ethoxylated fatty acids, esters of polyethylene glycol, ethoxylated monoglycerides and diglycerides of fatty acids, and ethylene oxide / propylene oxide block polymers. In some aspects, the surfactant is selected from polyethylene glycol ethers of fatty alcohols, particularly polyethylene glycol ethers having 20-40 ethylene oxide groups per unit. In some exemplary aspects, the surfactant is cetearyl alcohol polyether-25 or stearyl alcohol polyether-30. One or more surfactants are optionally present in a total amount of about 0.000001% to about 5%, depending on the formulation used and the type of surfactant. In some aspects, the amount of surfactant is about 0.000001% to about 0.00001% by weight of the composition, or about 0.00001% to about 0.0001%, or about 0.0001% to about 0.001%, or about 0.001% to about 0.01%, or about 0.01% to about 1%, or about 1% to about 5%.

[0082] In some aspects, the dental composition or formulation further comprises water and / or polyol. Typical polyols used in oral care compositions, particularly dental floss or toothpaste compositions, include humectants such as glycerin, sorbitol, polyethylene glycol, polypropylene glycol, propylene glycol, xylitol (and other edible polyols), hydrogenated partially hydrolyzed polysaccharides, and mixtures thereof. In some aspects, the polyol is glycerin and / or sorbitol. In some aspects, the amount of water and / or polyol depends on the nature of the formulation. In some exemplary aspects, the amount of water and / or polyol is at least 10 wt%, or at least 20 wt%, or at least 30 wt%, or at least 40 wt%, or at least 50 wt%, or at least 60 wt%, or at least 70 wt%, or at least 80 wt% based on the total weight of the composition.In some aspects, the levels of water and / or polyols should be less than 95 wt%, or less than 90 wt%, or less than 85 wt% or less than 80 wt% of the total composition.

[0083] In some aspects, the formulations or compositions of this disclosure contain about 5% to about 90% glycerol. In some aspects, glycerol may be present in the composition or formulation at about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or about 90%. In some aspects, glycerol may be present in the composition or formulation at about 10% to about 20%.

[0084] In some aspects, the formulations or compositions of this disclosure contain about 0.0000001% to about 0.01% of cetearyl alcohol polyether-25. In some aspects, cetearyl alcohol polyether-25 may be present in the composition or formulation at about 0.0000001%, 0.0000005%, about 0.000001%, about 0.000005%, about 0.00001%, about 0.00005%, about 0.0001%, about 0.0005%, about 0.001%, or about 0.01%. In some aspects, about 0.000001% to about 0.00001% of cetearyl alcohol polyether-25 may be present in the composition or formulation.

[0085] In some aspects, the formulations or compositions of this disclosure contain about 0.01% to about 10% of xanthan gum. In some aspects, xanthan gum may be present in the formulation or composition at about 0.001%, about 0.005%, about 0.01%, about 0.05%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%. In some aspects, about 0.1% to about 0.5% xanthan gum may be present in the composition or formulation.

[0086] In some aspects, the formulations or compositions of this disclosure contain about 0.1% to about 30% sorbitol.In some aspects, sorbitol may be present in the formulation or composition at about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, or about 30%. In some aspects, about 1% to about 10% of sorbitol may be present in the composition or formulation.

[0087] In some aspects, the formulations or compositions of this disclosure contain about 0.1% to about 50% silica. In some aspects, silicon dioxide comprises approximately 0.1%, approximately 0.2%, approximately 0.3%, approximately 0.4%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9%, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately 5%, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, approximately 20%, approximately 21%, approximately 22%, approximately 23%, approximately 24%, approximately 25%, approximately 26%, and approximately 27%. Approximately 28%, approximately 29%, approximately 30%, approximately 31%, approximately 32%, approximately 33%, approximately 34%, approximately 35%, approximately 36%, approximately 37%, approximately 38%, approximately 39%, approximately 40%, approximately 41%, approximately 42%, approximately 43%, approximately 44%, approximately 45%, approximately 46%, approximately 47%, approximately 48%, approximately 49%, or approximately 50% are present in the composition or formulation.

[0088] In some aspects, the formulations or compositions of this disclosure may further comprise a solvent, such as water. In some aspects, water may be present in the composition or formulation from approximately 0.01% to approximately 99%.In some respects, water can be approximately 0.1%, approximately 0.2%, approximately 0.3%, approximately 0.4%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9%, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately 5%, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, approximately 20%, approximately 21%, approximately 22%, approximately 23%, approximately 24%, approximately 25%, approximately 26%, approximately 27%, approximately 28%, approximately 29%, approximately 30%, approximately 31%, and approximately 32%. Approximately 33%, approximately 34%, approximately 35%, approximately 36%, approximately 37%, approximately 38%, approximately 39%, approximately 40%, approximately 41%, approximately 42%, approximately 43%, approximately 44%, approximately 45%, approximately 46%, approximately 47%, approximately 48%, approximately 49%, approximately 50%, approximately 51%, approximately 52%, approximately 53%, approximately 54%, approximately 55%, approximately 56%, approximately 57%, approximately 58%, approximately 59%, approximately 60%, approximately 71%, approximately 72%, approximately 73%, approximately 74%, approximately 75%, approximately 76%, approximately 77%, approximately 78%, approximately 79%, approximately 80%, approximately 81%, approximately 82%, approximately 83%, approximately 84%, approximately 85%, approximately 86%, approximately 87%, approximately 88%, approximately 89%, approximately 90%, approximately 91%, approximately 92%, approximately 93%, approximately 94%, approximately 95%, approximately 96%, approximately 97%, approximately 98%, or approximately 99% exist.

[0089] In some aspects, the pH of the compositions disclosed herein can be adjusted with a pharmaceutically acceptable acid, base, or buffer solution. The pH of the compositions disclosed herein is preferably in the range of about 6.0 to about 9.5, and more preferably in the range of about 6.1 to about 7.0 (e.g., about 6.1 to about 6.3 or about 6.7 to about 7.0).

[0090] In some aspects, the compositions or formulations provided herein can be prepared and used in various forms suitable for oral use, such as in the form of dental agents, including toothpaste, tooth powder, teething gel, mouthwash, oral spray, lozenges, chewing gum, dental paste, gingival massage cream, mouthwash tablets, or liquid formulations. In some aspects, the formulation is a dental agent. The term "dental agent" generally refers to a formulation used for cleaning oral surfaces. Dental floss is an oral composition that is not intentionally swallowed for the purpose of systemic administration of a therapeutic agent, but rather applied to the oral cavity for the purpose of treating the oral cavity and then spitting it out. In some cases, dental floss is used in conjunction with cleaning tools such as a toothbrush, typically by applying it to the bristles of the toothbrush and then brushing the accessible surfaces of the mouth. In other cases, dental floss is in the form of a paste or gel (or a combination thereof).

[0091] The dental cleaning compositions according to this disclosure may contain a mixture of water and polyol as an aqueous continuous phase in various relative amounts, wherein the amount of water is generally in the range of 10% to 50% by weight (based on the total weight of the dental cleaning agent), and the amount of polyol is generally in the range of about 20% to about 60% by weight (based on the total weight of the dental cleaning agent).

[0092] Oral care compositions, particularly toothpaste or dental cleaning compositions, may further contain additional abrasive materials. In some aspects, the abrasive material may be present in an amount of about 0.5% to about 75%, or about 3% to about 60% by weight based on the total weight of the paste. Suitable abrasive cleaners include silica dry gel, hydrogel and aerogel, and precipitated particulate silica; calcium carbonate, dicalcium phosphate, tricalcium phosphate, calcined alumina, sodium metaphosphate and potassium metaphosphate, sodium pyrophosphate and potassium pyrophosphate, sodium trimetaphosphate, sodium hexametaphosphate, particulate hydroxyapatite and mixtures thereof. In some aspects, the abrasive material is silicon dioxide, which is present in an amount of at least about 10%-15%, or 15%-20% or 20%-25%, or 25%-30% or 30%-35%, or 35%-40%, or 40%-45%, or 45%-50%, or 50%-55%, or 55%-60%, or 60%-70% or 70%-80% by weight.

[0093] In some aspects, the compositions of this disclosure may contain zinc ions. Preferably, the zinc ions are sourced from zinc chloride, zinc acetate, zinc gluconate, zinc sulfate, zinc fluoride, zinc citrate, zinc lactate, zinc oxide, zinc monoglyceride, zinc tartrate, zinc pyrophosphate, zinc maleate, and mixtures thereof.

[0094] In some aspects, the compositions of this disclosure may further contain optional ingredients conventional in the art, such as fluoride ion sources, buffers, flavoring agents, sweeteners, colorants, emulsifiers, preservatives, antisensitivity agents, bleaching agents, and antimicrobial agents.

[0095] In some aspects, the compositions of this disclosure may be substantially liquid in nature, such as mouthwash or cleansing agents. In such formulations, the medium is generally a water-alcohol mixture, and desiccants are desired to be included as described below. Typically, the weight ratio of water to alcohol is in the range of about 1:1 to about 20:1. In this type of formulation, the total amount of the water-alcohol mixture is generally in the range of about 70% to about 99.9% by weight of the formulation. The alcohol is generally ethanol or isopropanol.

[0096] In some aspects, the compositions may be solid, semi-solid, gel, or paste in nature, such as tooth powder, dental tablets, or toothpaste (dental cream) or gel dental cleaners. The medium for these solid or paste-like oral preparations typically contains dentally acceptable polishing materials.Non-limiting examples of polishing materials may include water-insoluble sodium metaphosphate, potassium metaphosphate, tricalcium phosphate, calcium phosphate dihydrate, anhydrous dicalcium phosphate, calcium pyrophosphate, magnesium orthophosphate, trimagnesium phosphate, calcium carbonate, hydrated alumina, calcined alumina, aluminum silicate, zirconium silicate, silica, bentonite, and mixtures thereof. Other suitable polishing materials may include particulate thermosetting resins, such as melamine-, phenolic, and urea-formaldehyde, as well as cross-linked polyepoxides and polyesters. In some aspects, polishing materials may include crystalline silica, silica gel or colloidal silica with a particle size of up to about 5 micrometers, an average particle size of up to about 1.1 micrometers, and a surface area of ​​up to about 50,000 cm² / g, and composite amorphous alkali metal aluminum silicates.

[0097] Polishing materials are typically present in solid or paste compositions at a weight concentration of about 10% to about 99%. In some aspects, polishing materials may be present in toothpaste at an amount of about 10% to about 75%, and in tooth powder at an amount of about 70% to about 99%. In toothpaste, when the polishing material is essentially silica, it is typically present at an amount of about 10% to 30% by weight. Other polishing materials are generally present at an amount of about 30% to 75% by weight.

[0098] In toothpaste, the liquid medium may generally contain water and a wetting agent in an amount ranging from about 10% to about 80% by weight of the formulation. Glycerin, propylene glycol, sorbitol, and polypropylene glycol exemplify suitable wetting agents / carriers. In some aspects, a liquid mixture of water, glycerin, and sorbitol may be used. In transparent gels where refractive index is an important consideration, about 2.5%–30% w / w water, 0%–about 70% w / w glycerin, and about 20%–about 80% w / w sorbitol may be used.

[0099] Toothpaste, cream, and gel generally contain natural or synthetic thickeners or gelling agents in proportions of about 0.1%–about 10%, preferably about 0.5%–about 5% w / w. Suitable thickeners may be synthetic lithium montmorillonite, a synthetic colloidal magnesium alkali metal silicate composite clay, for example, that can be obtained as Laponite (e.g., CP, SP 2002, D) sold by Laporte Industries Limited. Laponite D contains, by weight, about 58.00% SiO2, 25.40% MgO, 3.05% Na2O, 0.98% Li2O, and some water and trace metals. Other suitable thickeners, non-limiting examples, may include Irish moss, iota carrageenan, tragacanth gum, starch, polyvinylpyrrolidone, hydroxyethylpropyl cellulose, hydroxybutylmethylcellulose, hydroxypropylmethylcellulose, hydroxyethyl cellulose (e.g., available as Natrosol), sodium carboxymethyl cellulose, and colloidal silica, such as finely ground Syloid (e.g., 244).It may also include solubilizers, such as wetting polyols like propylene glycol, dipropylene glycol, and hexanediol; cellolytic agents, such as methyl cellolytic and ethyl cellolytic; vegetable oils and waxes containing at least about 12 carbons in their linear chains, such as olive oil, castor oil, and petrolatum; and esters, such as amyl acetate, ethyl acetate, and benzyl benzoate.

[0100] In addition, the toothpaste compositions of this disclosure may further contain pharmaceutical ingredients. Common toothpaste compositions contain appropriate pharmaceutical ingredients depending on the intended use, and fluoride, which forms a fluoride film on teeth to make them resistant to acids such as lactic acid, is recently recognized as indispensable for toothpaste compositions, as lactic acid is a metabolite of bacteria that cause tooth decay. In some aspects, the composition may contain sodium fluoride or sodium monofluorophosphate alone or in combination. In addition, for the prevention of periodontitis, water-soluble salts, such as sodium chloride, sodium bicarbonate with high osmotic pressure, aminocaproic acid, allantoin and allantoin derivatives, and various vitamins may be used concurrently.

[0101] In addition, the toothpaste composition of this disclosure may further include a binder. A binder that prevents the separation of solid powder components and liquid components is indispensable for ointment-type toothpastes, and any water-soluble macromolecule can be used. Commonly used binders include sodium carboxymethyl cellulose synthesized from tree cellulose, carrageenan extracted from seaweed, and xanthan gum obtained from microbial metabolism.

[0102] In addition, the toothpaste composition of this disclosure may further include a foaming agent. The foaming agent increases the usability of the product, aids in cleaning and promotes the dispersion and penetration of pharmaceutical ingredients, and reduces surface tension, thereby facilitating the separation of foreign substances. As a foaming agent, the anionic surfactant sodium lauryl sulfate is mainly used, and depending on the nature of the formulation, nonionic surfactants such as polyoxyethylene-polyoxypropylene copolymer (poloxam), polyoxyethylene hardened castor oil, and polyoxyethylene dehydrated sorbitan fatty acid esters may be used as supplementary agents.

[0103] Various other materials may be incorporated into the oral preparations of this disclosure, such as whitening agents, preservatives, silicones, chlorophyll compounds, and / or ammoniating materials such as urea, diammonium phosphate, and mixtures thereof. Where present, these adjuvants may be incorporated into the preparation in amounts that substantially do not adversely affect the desired properties and characteristics.

[0104] Any suitable flavoring or sweetening material may also be used. Non-limiting examples of suitable flavoring ingredients include flavoring oils such as spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, and orange oils, as well as methyl salicylate. Suitable sweeteners may include sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclohexanesulfonate, perilla, AMP (methyl aspartate), saccharin, etc. Suitably, flavorings and sweeteners may each or together constitute more than about 0.1% to 5% of the preparation.

[0105] The compositions of this disclosure may also be incorporated into lozenges, or into chewing gum or other products, for example by stirring into a warm gum base or coating the outer surface of a gum base, illustrative examples of which include jelutong, rubber latex, vinyl resin, etc., preferably together with conventional plasticizers or softeners, sugars or other sweeteners, or such as glucose, sorbitol, etc.

[0106] In some aspects, oral preparations may be packaged and sold or otherwise distributed with suitable labels. For example, a bottle of mouthwash will have a label that essentially describes it as a mouthwash or mouthwash and has its instructions for use; and toothpaste, cream, or gel will typically be in a collapsible tube, generally aluminum, lead-lined or plastic, or other squeeze, pump, or pressurized dispenser for metering the contents, with a label that essentially describes it as toothpaste, gel, or dental cream.

[0107] In another aspect, this disclosure provides compositions comprising the above-described compositions, a fluoride ion source, and a carrier. Such compositions may be dental compositions in the form of gels, liquids, solids, powders, creams, or lozenges.

[0108] In some aspects, this disclosure includes an oral hygiene device comprising the disclosed compositions or formulations. In some aspects, the dental compositions or formulations may be used with dental trays, capsule applicators, oral cleaning sticks, or dental floss.

[0109] In some aspects, dental trays may include articles shaped to at least partially cover one or more teeth, gums, or dental implants. In some aspects, dental trays may be arched, round, or semi-circular. In some aspects, dental trays may be dental appliances (e.g., orthodontic appliances or retainers), night guards, mouth protectors, treatment trays, full or partial dentures, braces, etc. In some aspects, dental trays may include an elastic polymer material that generally conforms to the patient's teeth and may be transparent, translucent, or opaque.

[0110] In some aspects, the dental trays of this disclosure can be prepared using casting and curing methods. In some aspects, the dental trays can be prepared by a method comprising the steps of: (a) preparing a polymerizable composition; (b) depositing the polymerizable composition in an amount sufficient to fill a master mold cavity onto a master mold surface; (c) filling the cavity by moving beads of the polymerizable composition between a pre-formed substrate (e.g., a PET film) and the master mold, wherein at least one of the substrate and the master mold is flexible; and (d) curing the composition.

[0111] In some aspects, the dental tray may be made of polymeric materials, which may include one or more of the following: amorphous thermoplastic polymers, semi-crystalline thermoplastic polymers and transparent thermoplastic polymers such as polycarbonate, thermoplastic polyurethane, acrylic, polysulfone, polypropylene, polypropylene / ethylene copolymer, cyclic olefin polymers / copolymers, poly-4-methyl-1-pentene or polyester / polycarbonate copolymers, styrene polymers, polyamides, polymethylpentene, polyetheretherketone, polyurethane, polyolefins including metallocene polyolefins, polyesters such as elastomeric polyesters (e.g., Hytrel), biodegradable polyesters such as polylactic acid, polylactic acid / glycolic acid, succinic acid and glycol copolymers, fluoropolymers including fluoroelastomers, polyacrylates, polymethyl methacrylates or any combination thereof. In another aspect, the material may be selected from transparent or substantially transparent semi-crystalline thermoplastics, crystalline thermoplastics, and composite materials, such as polyamides, polyethylene terephthalate, polybutylene terephthalate, polyester / polycarbonate copolymers, polyolefins, cyclic olefin polymers, styrene copolymers, polyetherimides, polyetheretherketones, polyethersulfones, polypropylene terephthalate, and mixtures and combinations thereof. In some aspects, the material may be a polymeric material selected from polyethylene terephthalate, polyethylene terephthalate glycol, polycyclohexylenedimethyleneterephthalate glycol, and mixtures and combinations thereof. In some respects, dental trays may comprise materials including styrene-acrylonitrile, cellulose acetate butyrate, cellulose acetate propionate, cellulose triacetate, polyethersulfone, polymethyl methacrylate, polyurethane, polyester, polycarbonate, polyvinyl chloride, polystyrene, polyethylene naphthalate, copolymers or blends based on naphthalic acid, polycyclic olefins, polyimide, and glass. In some respects, dental trays may be made of biodegradable materials.Non-limiting examples of suitable biodegradable polymers include polycarboxylic acids; polyanhydrides such as maleic anhydride polymers; polyorthoesters; poly-amino acids; polyethylene oxide; polyphosphazene; polylactic acid, polyglycolic acid and their copolymers and mixtures such as poly(L-lactic acid) (PLLA), poly(D,L-lactide), poly(lactic acid-co-glycolic acid) and 50 / 50 weight ratio (D,L-lactide-co-glycolic acid); polydioxanone; polypropylene fumarate; polyphenolic peptides; polycaprolactone and its copolymers and mixtures such as poly(D,L-lactide-co-caprolactone) and polycaprolactone co-butyl acrylate; polyhydroxybutyrate valerate and mixtures thereof; Polycarbonates include tyrosine-derived polycarbonates and acrylates, polyiminocarbonates and polydimethyltrimethylcarbonate; cyanoacrylates; calcium phosphate; polyglycosaminoglycans; macromolecules such as polysaccharides (including hyaluronic acid, cellulose and hydroxypropyl methylcellulose); gelatin; starch; dextran; and alginates and their derivatives, proteins and peptides; and mixtures and copolymers of any of the above. Biodegradable polymers may also be surface-erodible polymers, such as polyhydroxybutyrates and their copolymers, polycaprolactone, polyanhydrides (both crystalline and amorphous), and maleic anhydride. In some aspects, dental trays may be made of a single polymer material or may comprise multiple layers of different polymer materials.

[0112] In some aspects, the compositions or formulations provided herein may be prepared and used in various forms suitable for animals. In this respect, the compositions or formulations provided herein can be prepared and used in various forms, non-limiting examples of which may include pet toothbrushes and pet toothpaste, chew sticks, rubber toys, chew toys, treats, chew or nibble toys, pet food, pet snacks, pet teething gels, nuggets, powders, or dental appliances (e.g., dentures). The compositions or formulations provided herein can be incorporated into any disclosed form suitable for animals using methods known in the art.

[0113] (II) Methods for Removing Tartar This disclosure includes methods for reducing or removing tartar from the tooth surface in a subject in which it is desired. In some aspects, the subject is a human or non-human animal, including but not limited to cat, dog, cattle, horse, or primate subjects.

[0114] In some aspects, the methods for reducing or removing tartar include, for example, contacting the tooth surface of the subject with an effective amount of at least two tartar-targeting enzymes as disclosed herein.Contact can be made, for example, by applying a solution (e.g., an aqueous solution), a dental cleaning agent, or a dental composition or dental preparation as disclosed herein to the tooth surface, waiting for a period of time, and then rinsing the mouth (usually with water). It will be appreciated that the amount of time can vary depending on a range of factors, including the extent and severity of tartar buildup, the individual being treated, whether the treatment is performed in a professional office by a dental professional or at home, and other factors. For example, the solution may be applied to the tooth surface for periods of less than about 60 minutes, less than about 30 minutes, less than about 15 minutes, less than about 15 minutes, less than about 10 minutes, less than about 5 minutes, less than about 2 minutes, less than about 1 minute, or about 30 seconds.

[0115] Contact can be repeated and / or performed periodically, such as once or twice daily or more frequently, once every two days, once every three days, once every four days, once every five days, once every six days, once weekly, once every two weeks, once every three weeks, or once monthly, or once or twice a year, at approximately regular intervals. Further, the contact may be made before, during / in combination with, or after contact with an oral care agent such as toothpaste or mouthwash. Following contact with an enzyme or other biocatalyst solution or composition, disintegrated or loosened tartar may be further removed from the tooth surface and oral cavity by rinsing with water or another agent, manual scraping or wiping, brushing, and / or wiping. In some aspects, the method may include the use of the dental compositions provided herein, as well as additional dental treatments, routines, and / or procedures.

[0116] In some aspects, this disclosure includes a method for reducing or removing tartar in subjects in need of it, the method comprising contacting the tooth surface with an effective amount of the composition. In this aspect, the method for reducing or removing tartar in subjects in need of it comprises contacting the tooth surface with an effective amount of the composition comprising DNase I or a functional variant or derivative thereof and chymotrypsin or a functional variant or derivative thereof. In some aspects, the method reduces or removes tartar by about 1% or about 2% in subjects compared to the average of subjects or a group of subjects who do not use the disclosed compositions or formulations.Approximately 3%, approximately 4%, approximately 5%, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, approximately 20%, approximately 21%, approximately 22%, approximately 23%, approximately 24%, approximately 25%, approximately 26%, approximately 27%, approximately 28%, approximately 29%, approximately 30%, approximately 31%, approximately 32%, approximately 33%, approximately 34%, approximately 35%, approximately 36%, approximately 37%, approximately 38%, approximately 39%, approximately 40%, approximately 41%, approximately 42%, approximately 43%, approximately 44%, approximately 45%, approximately 46%, approximately 47%, approximately 48%, approximately 49%, approximately 50%, approximately 51%, approximately 52%. Approximately 53%, approximately 54%, approximately 55%, approximately 56%, approximately 57%, approximately 58%, approximately 59%, approximately 60%, approximately 71%, approximately 72%, approximately 73%, approximately 74%, approximately 75%, approximately 76%, approximately 77%, approximately 78%, approximately 79%, approximately 80%, approximately 81%, approximately 82%, approximately 83%, approximately 84%, approximately 85%, approximately 86%, approximately 87%, approximately 88%, approximately 89%, approximately 90%, approximately 91%, approximately 92%, approximately 93%, approximately 94%, approximately 95%, approximately 96%, approximately 97%, approximately 98%, approximately 99%, approximately 100% or more. In some aspects, the disclosed formulations or compositions reduce or remove stones by at least 40%.

[0117] In some aspects, the formulations or compositions of this disclosure can be used in methods for preventing stones in subjects who require them. In this respect, prevention of dental calculus in subjects who require it involves contacting the tooth surface with an effective amount of a composition containing DNase I or a functional variant or derivative thereof and chymotrypsin or a functional variant or derivative thereof.In some respects, compared with the average of subjects or subject groups who did not use the disclosed compositions or formulations, this method prevented tartar buildup in subjects by approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, and 49%. About 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100% or more.

[0118] In some aspects, the formulations or compositions of this disclosure can be used in methods of improving palatability in subjects who require them. In this aspect, methods of improving palatability in subjects who require them include contacting a tooth surface with an effective amount of a composition comprising DNase I or a functional variant or derivative thereof and chymotrypsin or a functional variant or derivative thereof.In some respects, compared with subjects or the average of a subject population that did not use the disclosed compositions or formulations, the method improved palatability in subjects by approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, and 49%. Approximately 50%, approximately 51%, approximately 52%, approximately 53%, approximately 54%, approximately 55%, approximately 56%, approximately 57%, approximately 58%, approximately 59%, approximately 60%, approximately 71%, approximately 72%, approximately 73%, approximately 74%, approximately 75%, approximately 76%, approximately 77%, approximately 78%, approximately 79%, approximately 80%, approximately 81%, approximately 82%, approximately 83%, approximately 84%, approximately 85%, approximately 86%, approximately 87%, approximately 88%, approximately 89%, approximately 90%, approximately 91%, approximately 92%, approximately 93%, approximately 94%, approximately 95%, approximately 96%, approximately 97%, approximately 98%, approximately 99%, approximately 100% or more.

[0119] In some aspects, the compositions or formulations disclosed herein may be given to a subject after professional dental cleaning. In some aspects, the compositions or formulations disclosed herein may be given to a subject before a predetermined professional dental cleaning. In some aspects, the compositions or formulations disclosed herein may be given to a subject during professional dental cleaning.

[0120] In some aspects, the method of administration includes brushing teeth for about 10 seconds to about 120 seconds with a formulation or composition of the present disclosure.In some aspects, brushing teeth may include brushing with a formulation or composition for approximately 10 seconds, 11 seconds, 12 seconds, 13 seconds, 14 seconds, 15 seconds, 16 seconds, 17 seconds, 18 seconds, 19 seconds, 20 seconds, 21 seconds, 22 seconds, 23 seconds, 24 seconds, 25 seconds, 26 seconds, 27 seconds, 28 seconds, 29 seconds, 30 seconds, 31 seconds, 32 seconds, 33 seconds, 34 seconds, 35 seconds, 36 seconds, 37 seconds, 38 seconds, 39 seconds, 40 seconds, 41 seconds, 42 seconds, 43 seconds, 44 seconds, 45 seconds, 46 seconds, or 47 seconds. (Instruction manual page 17 / 35, 20 CN 121463944 A) 48 seconds, approximately 49 seconds, approximately 50 seconds, approximately 51 seconds, approximately 52 seconds, approximately 53 seconds, approximately 54 seconds, approximately 55 seconds, approximately 56 seconds, approximately 57 seconds, approximately 58 seconds, approximately 59 seconds, approximately 60 seconds, approximately 61 seconds, approximately 62 seconds, approximately 63 seconds, approximately 64 seconds, approximately 65 seconds, approximately 66 seconds, approximately 67 seconds, approximately 68 seconds, approximately 69 seconds, approximately 70 seconds, approximately 71 seconds, approximately 72 seconds, approximately 73 seconds, approximately 74 seconds, approximately 75 seconds Approximately 76 seconds, approximately 77 seconds, approximately 78 seconds, approximately 79 seconds, approximately 80 seconds, approximately 81 seconds, approximately 82 seconds, approximately 83 seconds, approximately 84 seconds, approximately 85 seconds, approximately 86 seconds, approximately 87 seconds, approximately 88 seconds, approximately 89 seconds, approximately 90 seconds, approximately 91 seconds, approximately 92 seconds, approximately 93 seconds, approximately 94 seconds, approximately 95 seconds, approximately 96 seconds, approximately 97 seconds, approximately 98 seconds, approximately 99 seconds, approximately 100 seconds, approximately 101 seconds, approximately 102 seconds The time intervals are approximately 103 seconds, 104 seconds, 105 seconds, 106 seconds, 107 seconds, 108 seconds, 109 seconds, 110 seconds, 111 seconds, 112 seconds, 113 seconds, 114 seconds, 115 seconds, 116 seconds, 117 seconds, 118 seconds, 119 seconds, or 120 seconds. In some aspects, brushing teeth includes brushing with the formulation or composition for about 30 seconds.

[0121] In some aspects, the method of administration includes using a dental tray having the formulation or composition of the present disclosure for about 1 minute to about 60 minutes.In some respects, dental trays containing formulations or compositions can provide approximately 1 minute, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 21 minutes, 22 minutes, 23 minutes, 24 minutes, 25 minutes, 26 minutes, 27 minutes, 28 minutes, 29 minutes, 30 minutes, 31 minutes, 32 minutes, or 33 minutes of oral stimulation. Approximately 34 minutes, approximately 35 minutes, approximately 36 minutes, approximately 37 minutes, approximately 38 minutes, approximately 39 minutes, approximately 40 minutes, approximately 41 minutes, approximately 42 minutes, approximately 43 minutes, approximately 44 minutes, approximately 45 minutes, approximately 46 minutes, approximately 47 minutes, approximately 48 minutes, approximately 49 minutes, approximately 50 minutes, approximately 51 minutes, approximately 52 minutes, approximately 53 minutes, approximately 54 minutes, approximately 55 minutes, approximately 56 minutes, approximately 57 minutes, approximately 58 minutes, approximately 59 minutes, or approximately 60 minutes. In some aspects, the dental tray containing the formulation or composition may be administered for approximately 30 minutes.

[0122] In some aspects, the compositions or formulations of this disclosure may be administered at least once a day. In some aspects, the compositions or formulations may be administered at least twice a day. In some aspects, the compositions or formulations may be administered at least three times a day. In some aspects, the compositions or formulations may be administered more than three times a day.

[0123] In some aspects, the method includes brushing teeth with a formulation or composition of the present disclosure, followed by brushing teeth with commercially available toothpaste. In some aspects, the method includes brushing teeth with commercially available toothpaste, followed by brushing teeth with a formulation or composition of the present disclosure.

[0124] In some aspects, the method includes sequentially brushing teeth with a composition or formulation of the present disclosure, and using a dental tray containing a formulation or composition of the present disclosure. Brushing teeth with a formulation or composition of the present disclosure, followed by using a dental tray having the formulation. In some aspects, the method includes using a dental tray having a formulation or composition of the present disclosure, followed by brushing teeth with a formulation or composition of the present disclosure. In some aspects, the method includes brushing teeth with a formulation or composition of the present disclosure, followed by using a dental tray having a formulation or composition of the present disclosure, followed by brushing teeth with a formulation or composition of the present disclosure.

[0125] In some aspects, the treatment method may include single, multiple, and repeated administration of the compositions or formulations disclosed herein as needed for the prevention or treatment of a disease or condition (e.g., calculi) suffered by a subject. In some respects, treatment methods may include evaluating stone levels in subjects before, during, or after treatment. In other respects, treatment may continue until a reduction in stone levels can be detected in subjects.

[0126] In some aspects, the effective dose of the compositions or formulations disclosed herein may include, but is not limited to, for example, about 0.00001, 0.0001, 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.25, 1.5, 1.75, 2, 2.5 or 3-10,000 mg / kg / day, or as required by a particular composition or formulation.

[0127] For the disclosed compositions or formulations, the dosage may also be in International Units (IU) per day (lU / day) and is approximately 100 lU / day, 200 lU / day, 300 lU / day, 400 lU / day, 500 lU / day, 600 lU / day, 700 lU / day, 800 lU / day, 900 lU / day, 1000 lU / day, 1100 lU / day, 1200 lU / day, 1300 lU / day, 1400 lU / day, 1500 lU / day, 1600 lU / day, 1700 lU / day, 1800 lU / day, 1900 lU / day, 2000 lU / day, 2100 lU / day, 2200 lU / day, etc. 2300 lU / day, 2400 lU / day, 2500 lU / day, 2600 lU / day, 2700 lU / day, 2800 lU / day, 2900 lU / day, 3000 lU / day, 3100 lU / day, 3200 lU / day, 3300 lU / day, 3400 lU / day, 3500 lU / day, 3600 lU / day, 3700 lU / day, 3800 lU / day, 3900 lU / day, 4000 lU / day, 4500 lU / day, 5000 lU / day, 5500 lU / day, 6000 lU / day, 6500 lU / day, 7000 lU / day, 7500 lU / day, 8000 lU / day, 9000 lU / day lU / day, 10,000 lU / day, 20,000 lU / day, 30,000 lU / day, 40,000 lU / day, 50,000 lU / day, 60,000 lU / day, 70,000 lU / day, 90,000 lU / day, 100,000 lU / day, 200,000 lU / day, 300,000 lU / day, 400,000 lU / day, 500,000 lU / day, 600,000 lU / day, 700,000 lU / day, 800,000 lU / day, 900,000 lU / day, 1,000,000 lU / day, 1,100,000 lU / day 1,200,000 lU / day, 1,300,000 lU / day, 1,400,000 lU / day, or 1,500,000 lU / day.

[0128] The dosage and interval can be adjusted individually to provide the desired effect, or to be sufficient to maintain the therapeutic or preventative effect.

[0129] The specific dosage and treatment regimen for any particular subject will depend on a variety of factors, including the activity of the specific enzyme used, the severity of the stones in the subject and the process of stone accumulation, the condition or symptoms, the patient's management of the condition or symptoms, and the judgment of the treating physician.

[0130] The effective amount may be administered once or multiple times, by application, or by dose. The therapeutically effective amount (i.e., the effective dose) of the formulation depends on the type of composition or formulation selected. Furthermore, treatment of a subject with the effective amount of the formulation or composition described herein may include a single treatment or a series of treatments. For example, the effective amount may be administered at least once. The composition may be administered once or multiple times daily to once or multiple times weekly; including every other day. Those skilled in the art will recognize that certain factors may affect the dosage and duration required to effectively treat a subject, including but not limited to the severity of the stones, prior treatment, the subject's overall health or age, and any other pre-existing conditions.

[0131] After administration, the subject may be assessed to detect, evaluate, or determine their stone level. In some cases, treatment may continue until a change in the disease level (e.g., a reduction) can be detected in the subject. After a patient’s condition improves (e.g., a change in calculus levels in the subject (e.g., a decrease)), a maintenance dose of the formulations or compositions disclosed herein may be given if necessary. Subsequently, the dose or frequency, or both, may be reduced, for example as a function of calculus buildup, to maintain the improved condition level. However, after any recurrence of calculus buildup, the patient may require long-term intermittent treatment.

[0132] In some aspects, the compositions disclosed herein may include other compounds, drugs, or agents for treating calculus, plaque, and / or periodontal disease. For example, in some cases, the compositions disclosed herein may be combined with one or more (e.g., one, two, three, four, five, or fewer than ten) compounds. When administered co-administered, the formulations or compositions disclosed herein may work together with other agents for treating calculus, plaque, and / or periodontal disease to produce a mechanically additive or synergistic therapeutic effect.

[0133] (III) Kits A further aspect of this disclosure provides kits comprising an amount of any one or any combination of the disclosed dental compositions or formulations as detailed above. The kit optionally includes one or more brushes, toothpicks, dental trays, and / or applicators for applying any of the enzyme solution, composition, or formulation to the teeth and then removing disintegrated tartar from the tooth surface. Kit components may be supplied together with other kit components in a suitable container, such as any commercially available container or packaging. Kits provided herein typically include instructions for carrying out the methods detailed herein. The instructions included in the kit may be affixed to packaging material or included as a packaging insert. Although the instructions are generally in written or printed form, they are not limited thereto.This disclosure contemplates any medium capable of storing such instructions and transmitting them to an end user. Such media include, but are not limited to, electronic storage media (e.g., disks, magnetic tapes, magnetic tape instruction manuals 19 / 35 pages 22 CN 121463944 A boxes, chips), optical media (e.g., CD ROMs), etc. As used herein, the term “instructions” may include the address of an Internet site providing instructions.

[0134] Not intended to be theoretically bound, it is believed that the current compositions and methods are so effective in breaking down and removing tartar, in part, due to the way tartar accumulates and is constructed. The inventors’ work shows that dental plaque has a layered structure, including an internal gel or gel-like structure on which one or more layers of calcium-cross-bridged extracellular DNA (eDNA) and proteins in a cross-linked network structure are stacked. The internal gel or gel-like portion contains aqueous contents similar to those of salivary gland contents. Aqueous contents may include inorganic substances, calcium, phosphates, hydroxyapatite, proteins and glycoproteins, amylases, polyproline proteins, and mucins. In addition, dental plaque may contain contents from non-salivary gland sources, including transglutaminase from the oral epithelial surface and chymotrypsin from the keratinocytes of the soft palate. Dental plaque may further include contents from non-host sources, such as bacterial cells from the oral microbiome, eDNA secreted from the microbiome, and proteins and polysaccharides from food. The outermost layer of plaque contains calcium-cross-bridged eDNA (about 0.01%) and proteins (about 0.04%–0.05%), wherein the proteins include negatively charged mucin glycoproteins and cross-linked network structures of transglutaminase.

[0135] Furthermore, the inventors have determined that the plaque calcification process can begin immediately, with plaque becoming approximately 50% calcified within 2 days and 60%–90% calcified within approximately 12 days. This calcification process is also gradual, thereby adding continuous layers and thus transforming the calculus structure from a more two-dimensional to a more three-dimensional structure. Although the network structure of calcium-cross-bridged eDNA and mucin glycoprotein is reversible, the network structure formed by transglutaminase cross-linking of proteins is irreversible. Compositions and methods of this disclosure have been developed to effectively target the contents and formation process of stone-forming structures, aiding in the treatment or prevention of stones, as described in the following examples. Examples

[0136] Example 1: Anti-stone enzyme formulation with DNase 1 and chymotrypsin An anti-stone enzyme composition containing DNase 1 and chymotrypsin was formulated as provided. Two batches were prepared, namely Formulation I and Formulation II, containing different levels of the nonionic surfactant cetearyl alcohol polyether and water.

[0137] For Formulation I, the chemical components disclosed in Table 1 were thoroughly mixed.

[0138] Table 1: Chemical composition of formulation I Stock solution volume / volume Glycerin 90 ml 10% Cetearyl alcohol polyether-25 36 ml 2% Xanthan gum 90 ml 80% Sorbitol 36 ml Water 30 ml Silica 72 g Discard approximately 110 ml of the combined volume. Then the enzymes were mixed in batches into the solution. 5 g of DNase 1 (4270 Kunitz units / mg) was added to the combined solution and mixed until homogeneous. 5 g of chymotrypsin (66.6 units / mg) was added to the solution and mixed until homogeneous. This step was repeated 6 times to obtain an approximate enzyme activity of 185,652.17 units / ml for DNase and an activity of 2,895.65 units / ml for chymotrypsin. The formulation was filled into capped syringes (1 ml / syringe) and refrigerated until administration.

[0139] Similarly, formulation II was prepared by initial dissolution of the chemical components provided in Table 2.

[0140] Table 2: Chemical composition of formulation II, 20 / 35 pages, 23 CN 121463944 A. Stock solution volume / volume: Glycerin 90 ml, 10 cetearyl alcohol polyether-25 0.36 ml, 2% xanthan gum 90 ml, 80% sorbitol 36 ml, silica 72 g. To control volume, for this formulation, the volume was compensated to 200 ml with water. The enzyme was then mixed into the solution in batches. 5 g of DNase 1 (3900 Kunitz units / mg) was added to the solution and mixed until homogeneous. Next, 5 g of chymotrypsin (66.6 units / mg) was added to the solution and mixed until homogeneous. This step was repeated 6 times and an additional 30 ml of water was added. To obtain sufficient volume for the experiment, 50 ml of formulation I was added to this formulation. The approximate DNase 1 activity of the formulation was determined to be 183,300 Kunits / ml and the chymotrypsin activity to be 114 units / ml. The formulation was filled into capped syringes (1 ml / syringe) and refrigerated until administration.

[0141] Syringes filled with formulation II were used in clinical studies to evaluate the efficacy and safety of calculi treatment in human subjects.

[0142] Example 2: In vivo study evaluating the anticalculi activity and safety profile of a dental formulation The safety and efficacy of a formulation containing DNase 1 and chymotrypsin in removing existing calculi deposits were investigated in subjects. Between-group and within-group comparisons were performed during the 4-week trial period. A schematic diagram of the study design is provided in Figure 1.

[0143] Recruitment Forty subjects were recruited for these trials. Trial eligibility was based on the following eligibility criteria.

[0144] Inclusion Criteria To be included in the study, each participant must: 1. Provide written informed consent to participate in the study; 2. Be at least 18 years old; 3. Agree not to participate in any other oral / dental product studies during the study period and to use only the designated oral hygiene products (including toothbrushes, toothpaste, home remedies, thread, or other products such as chewing gum, mouthwash, tongue cleaners, etc.) throughout the study; 4. Agree to avoid any selective dental procedures (including non-study dental prevention) until the study is completed; 5. Agree to avoid any non-study oral hygiene and whitening products; 6. Be in good general health, as determined by the investigator / designated personnel based on a review of the participant's health history / current condition; 7. Have 6 mandibular anterior teeth without crowns or veneers; 8. Agree to comply with the study procedures and schedule, including follow-up; 9. Have at least 9 mm of tartar on the 6 mandibular anterior teeth and report that they have had dental cleanings in the previous 2–6 months.

[0145] Exclusion Criteria: Subjects are excluded from study participation if they meet any of the following criteria: 1. Having a medical condition requiring pre-operative antibiotics prior to dental procedures; 2. Routinely using chlorhexidine mouthwash; 3. Having any oral condition or pathology that may interfere with study compliance and / or examination procedures (e.g., extensive caries, long-term neglect, advanced periodontitis); 4. Having a current history of oral or oropharyngeal cancer; 5. Reported pregnancy or breastfeeding by the subject; 6. Not brushing teeth routinely; 7. Having any condition that may make the subject's participation in the study unsafe, at the investigator's discretion.

[0146] Deferral Criteria: Subjects are excluded from the study and analysis if they: 1. Have participated in any other oral / dental product study since the last visit; 2. Have received any elective dentistry since the last visit; 3. Have used any oral hygiene product other than the designated study product; 4. Are unable or unwilling to comply with the product instructions for any reason.

[0147] After subjects meet the inclusion / exclusion criteria, their calculus status is examined. Only subjects with at least 9 mm of calculus accumulated on the lingual surface of the 6 mandibular anterior teeth are eligible. The details of the protocol are discussed with each potential subject, and written informed consent is obtained from all subjects before any activities related to the clinical study. Subjects may withdraw their consent at any time without bias. A Subject Responsibility Form (CRF) is completed for each subject. If a subject does not complete the study for any reason, an explanation is entered on the Subject Responsibility Form (CRF).

[0148] The following visits were conducted during the study period: Visit 1 (Informed Consent, Baseline, and Impressions): During Visit 1, participants received an explanation of the nature and process of the study, signed an informed consent form, and received a copy of the signed consent form. After the participants signed the informed consent form, the researchers conducted oral examinations and reviewed the inclusion / exclusion criteria to ensure eligibility. Demographic details (including age, sex, and race), medical history, and concomitant medications were assessed for eligible participants. Demographic information and inclusion / exclusion criteria were also obtained and captured in appropriate case report forms (CRFs). Participants were assessed to ensure that at least 9 mm of calculus was present on the lingual surface of the 6 mandibular anterior teeth. Eligible participants were randomized to the treatment group.

[0149] Participants were randomly assigned to one of three study groups using a randomization program developed and maintained by an independent statistician. Participants were stratified by baseline lingual V-MI calculus score and sex (see Figure 2).

[0150] During Visit 1, all randomized subjects (except the custom tray test group who returned the next day) underwent their first use under supervision at the study site.

[0151] Subjects used the product at home twice daily for a 4-week period. Each product use was performed according to the group instructions. Subjects received a diary card to record home treatment.

[0152] Subjects randomized to the enzyme composition gel group with the custom mouthguard received an impression at this visit. Impressions of the mandibular teeth were used to construct individual mouthguards for use during the clinical trial. The mouthguards were constructed from vacuum-formed mouthguard plastic. Each mouthguard was trimmed to include only the teeth and gingival margins and eliminated contact with the cervical margin of each tooth to isolate the enzyme composition gel from contact with the robust tooth surface.

[0153] Visits 2 and 3 (2-week and 4-week check-ups): During Visits 2 and 3 (after treatment 2 and 4 weeks, respectively), the persistence criteria were evaluated and recorded on the appropriate CRF. After verification of continuing eligibility, safety was evaluated and adherence to the study protocol was assessed via dental examination. Stone deposits were evaluated to replicate the assessment performed at Visit 1. Instructions for use 22 / 35 pages 25 CN 121463944 A

[0154] Table 3 provides an overview of the visits: Table 3: Study Procedures and Schedule Identification of Study Products The products used during this study are listed below: 1. ADA Reference Soft Hand Brush: (Colgate® Classic [Pokey], Colgate-Palmolive Co., New York, NY) Used with ADA toothpaste.

[0155] 2. ADA Reference Soft Hand Brush: Used with the formulation only.

[0156] 3. Enzyme formulation: Formulation II, as provided herein.

[0157] 4. ADA-approved standard fluoride toothpaste: Crest® Cavity Protection Cool Mint Gel, 0.243% sodium fluoride, Procter & Gamble, Cincinnati, OH 45202.

[0158] Calculus measurement 1. Calculate the Volpe-Manhold index (V-MI) on the lingual surfaces of the six lower anterior teeth (see Figure 2). Volpe-Manhold index (V-MI) 2. Measure calculus present on the lingual surfaces of the six lower anterior teeth. The instrument used was a standard periodontal probe, with a scale unit of millimeters. After the teeth were dried with airflow, the instrument was placed at the lowest edge of the visible calculus and measurements were taken on the following three planes: (a) the center of the lingual surface was bisected; (b) diagonally across the mesial incisal angle of the tooth, through the area of ​​maximum calculus height; and (c) diagonally across the distal end angle of the tooth, through the area of ​​maximum calculus height.

[0159] The examiner then assigned a score to each measurement plane. Measurements were made in increments of 0.5 mm, starting at 0.5. A score of (0) indicated the absence of calculus at the measurable site. The V-MI for each subject was calculated by summing the millimeter scores of all rated sites.

[0160] Digital photographs of the lingual surfaces of the six lower anterior teeth were taken.

[0161] Methodology and Study Design This study was conducted as a randomized, single-blind, single-center, parallel-group, three-treatment clinical trial designed to evaluate the safety and efficacy of the enzyme formulation in removing calculus accumulation. Subjects underwent a Volpe-Manhold Index (V-MI) calculus examination as described below at each visit.

[0162] Forty (40) subjects with at least 9 mm of calculus on the lingual side of their mandibular anterior teeth were eligible to continue in the study according to the eligibility criteria. Subjects were randomly assigned to one of three groups (20 subjects in the control group and 10 subjects in each test group).

[0163] All treatment groups brushed their teeth for 2 minutes twice daily with an ADA-approved toothbrush and dental cleaning agent. The three groups followed the following protocol: Test Group A: Brushed their teeth for 2 minutes twice daily with a control toothbrush and Crest.

[0164] Test Group B: Brushed their teeth for 1 minute with a toothbrush using half the amount of enzyme formulation in the syringe (1 ml / syringe). Subjects were instructed to start brushing on the lingual side of their lower incisors with a separate toothbrush and finish on the same teeth.Then, the subject brushed their teeth with control toothpaste, spat it out, re-administered the remaining amount in the syringe, emptied the syringe containing the enzyme formulation, and brushed their teeth again for another minute, starting on the lingual side of the lower incisors and ending there after brushing for 1 minute, then spat it out and did not rinse. Brushing with the enzyme formulation was completed at least 30 minutes before the control brushing. The subject was instructed to spit out the enzyme formulation after use but not rinse for at least 30 minutes. The subject then brushed their teeth twice daily with the control toothbrush and Crest toothpaste for two minutes each time. In total, the subject brushed their teeth four times a day, twice with the enzyme formulation and twice with Crest. The control toothbrush was rinsed daily with hot water until clean.

[0165] Test Group C: Before using the custom tray, the subject brushed their teeth for 1 minute using a separate toothbrush designated only for the enzyme formulation, applying half a syringe (1 ml / syringe), then spat it out and did not rinse. A custom tray was filled with the enzyme formulation from a second syringe and worn once daily for 30 minutes. The tray was removed, and the subject brushed his / her teeth for 1 minute with the remaining enzyme preparation from the first syringe, spat it out, and left it unwashed for at least 30 minutes. The subject completed his / her oral care routine by brushing his / her teeth for two minutes twice a day with a control toothbrush and toothpaste (Crest). The control toothbrush was rinsed with hot water daily until clean.

[0166] Subjects were stratified according to the level of calculus and sex obtained during the screening / baseline examination. During the 4-week test period, subjects brushed their teeth twice a day without supervision and returned at weeks 2 and 4 for safety and V-MI examinations.

[0167] Evaluation and Data Collection The test phase of the study included a total of 56 treatment sessions and 3 clinical visits over a 4-week period. Evaluation data were collected for each subject at baseline, 2, and 4 weeks. The mean dataset for each group was calculated.

[0168] Study endpoints and efficacy evaluation: The following endpoints were set for this study: Primary endpoint: 1. After 4 weeks of treatment, there was a significant reduction in calculus in the test group compared to the control group.

[0169] 2. Significant reduction in stones in the test group compared to longitudinal within-group values.

[0170] 3. Safety assessment based on adverse events in either test group after 4 weeks of treatment.

[0171] 4. Reduction in stones by removal of existing deposits and / or prevention of new deposits.

[0172] Secondary endpoints: 1. Prevention of stone accumulation in the treatment group, as evidenced by no significant increase in stone score compared to baseline.

[0173] 2. Significant reduction in stones in the test group after 2 weeks of treatment, compared to the control group.

[0174] Exploratory endpoints 1. Any difference in taste when the patient rubs their tongue against the back of their incisors? 2. Any improvement in the patient's breath? 3. Any change in tooth appearance or color. An analysis set was performed, including all subjects who used the experimental gel at least once. The performance analysis set consisted of all subjects who provided at least one post-treatment performance measurement. Only observed data were used; missing data were not entered.

[0175] Subject treatment safety analysis set was used to describe subject treatment.

[0176] Subject treatment was tabulated; the number of subjects enrolled, exposed, prematurely terminated, and completed was summarized. A withdrawal / termination list was prepared, including the reason for termination and the time of termination.

[0177] Safety analysis The safety analysis was descriptive in nature, with SAEs and AEs tabulated by body system, preference, severity, and relationship to the study gel. In relevant cases, events were correlated with remote log file data. In addition, safety complaints described by subjects were described and investigated.

[0178] Oral examinations were performed according to the OSHT - Oral Soft & Hard Tissue Assessment. The soft and hard tissues of the oral cavity were evaluated by visual examination of the oral cavity and perioral region using a standard dental lamp, dental mirror, and gauze. Structures examined included the gingiva (free and attached), hard and soft palate, oropharynx / uvula, buccal mucosa, tongue, floor of mouth, labial mucosa, buccal / labial mucosal folds, lips, teeth, and perioral region. All abnormal findings that might be product-related and noticed after product dispensing, whether not recorded at baseline or present at baseline but worsened during product use, were recorded on the AECRF.

[0179] Performance analysis was determined by the reduction of calculus within the treatment group (longitudinal analysis) and between the groups compared to the control group after 4 weeks of treatment. Additionally, efficacy was determined by the prevention of calculus accumulation in the treatment group, as evidenced by no significant increase in calculus score compared to baseline.

[0180] The primary outcome was calculated using the Volpe-Manhold index, and all other variables were considered minor. The stone scores of this index were summed to provide a total score for each oral cavity at each clinical examination. Although the analysis was performed at other measurement time points during the study period, the primary time point was at the end of the trial, four weeks after product use.

[0181] The statistical significance of the mean data for age and scoring indices was determined parametrically by analysis of variance to test for differences between product groups. If necessary, inter-group comparisons for each parameter were performed by multiple range tests, with gender compensation. Data from all subjects who completed the final evaluation were used in the analysis.

[0182] Data for each scoring index were also analyzed by analysis of covariance using baseline data as covariates.Including covariates (baseline data) in the statistical model improves the accuracy of determining the impact of the test product on the scores. The adjusted mean generated by this procedure compensates for any differences present in the baseline data between treatment groups. This reduces variation and increases power, and also adjusts for baseline imbalances due to subject attrition.

[0183] Longitudinal (i.e., within-treatment) comparisons of the VMI mean were performed using a one-sample t-test based on the change from baseline to the final examination.

[0184] All comparisons were performed using two-tailed tests at an overall significance level of 0.05. Summary statistics were provided for all time points. Safety data were summarized. Adverse events experienced by all subjects receiving the test product were included in the safety analysis. Adherence to the study protocol, as well as accuracy and completeness, were examined for all cases. Cases that did not meet these requirements were excluded from the initial analysis.

[0185] Post-efficacy analyses were performed on endpoints determined to be non-statistically significant. Therefore, the sample size required for an appropriately driven study was determined.

[0186] All reported adverse events were listed, with details of duration, outcome, severity, and possible relationship to the study product. The frequency of subjects experiencing one or more adverse events during the trial was tabulated and compared across treatment groups. If necessary, the likelihood ratio chi-square test was used to compare the frequency of subjects experiencing adverse events in each treatment group.

[0187] Results Study Group / Enrollment: The final list of enrolled subjects is provided in Table 4: Table 4: Enrollment and Withdrawal Data Subject # Recruitment / Reservation 44 Cancellation / Non-attendance 0 Subject Consent 44 Screening / Baseline Failure 4 Randomization to Product 40 Acceptance of Product 40 Disqualification / Withdrawal 2 Completion 38 Subject Withdrawal / Disqualification 2 All subjects who completed the study demonstrated satisfactory adherence. Forty subjects were randomized and 38 completed the study. Of the randomized subjects, 22 were female and 18 were male. The mean age was 50.4 years, with a minimum age of 23 years and a maximum age of 74 years. Baseline stone scores were similar across all treatments.

[0188] Oral tissue examination was performed, including the gingiva (free and attached), hard and soft palate, oropharynx, buccal mucosa, tongue, floor of mouth, labial mucosa, buccal / labial mucosal folds, lips, and perioral region. No evidence of any hard or soft tissue damage related to the use of the test product was observed and / or reported. An overview of adverse events observed during the examination or self-reported by the subjects is provided in Table 5.

[0189] Table 5: Overview of Adverse Events # Group Examiner or Self-Reported AE AE Rating Product-Related Resolved Within 5 Days Based on Treatment Resolved 1019 A Examiner Gingival Marginal Wear (Toothbrush) #26 Mild Possibly Caused by Brushing Yes Yes 1024 B Examiner Gingival Marginal Erythema #27 Mild Possibly Caused by Brushing Yes Yes 1032 B Examiner Gingival Marginal Erythema #24 & 28 Mild Possibly Caused by Brushing Yes Yes 1044 B Examiner Anterior Tongue Papillary Inflammation Mild Possibly No Instructions for Use 26 / 35 Page 29 CN 121463944 A 1013 C Examiner Gingival Marginal Erythema #23-26 Moderate Possibly Caused by Brushing Yes Yes 1044 Self-Reported Tongue Burning NA Possibly No 1012 C Self-Reported Gingival Sensitivity NA Possibly Yes 1012 C Self-Reported Lip Sensitivity NA It is possible that all adverse events were resolved within the 5-day reassessment period. All adverse events (inspector and self-reported) observed in test groups B and C were attributed to the test product. Erythema was most likely caused by a 4-times-daily brushing procedure compared to the control group brushing twice daily. Adverse events in subject 1019 were toothbrush abrasion.

[0190] Clinical study results: A summary of data on Volpe-Manhold index scores and changes from baseline to week 4 for each of the three treatments is provided in Tables 6 and 7 and Figure 3. During the 4-week study, both treatments with the enzyme formulation reduced calculus. During the 4-week study, treatment with the enzyme formulation alone reduced calculus by 40.0%, while treatment with the enzyme formulation plus a custom tray containing the enzyme formulation reduced calculus by 38.1%. Longitudinal within-group analysis results showed that during the 4-week study, both groups treated with the enzyme formulation had statistically significant calculus reductions (p<0.001). The reductions were similar in both groups. In contrast, the control group showed a statistically significant increase in stones of 12.2% (p<0.001) over the 4-week study period. The reduction at 2 weeks was 0.8% in the enzyme formulation group and 1.6% in the enzyme formulation plus customized tray group.

[0191] Table 6: Volpe-Manhold Index Score Instructions 27 / 35 pages 30 CN 121463944 A Table 7: Changes in Volpe-Manhold Index Score over 4 Weeks Table 8 shows that both enzyme formulation treatments showed statistically superior stone reduction compared to the control group (p<0.001).

[0192] Table 8: ANCOVA of VM-I Stone Score at Week 4 Table 9 provides the week 4 analysis of covariance results. As shown in Table 7, neither group treated with the active enzyme formulation showed a clinically or statistically significant reduction at week 2.The confidence intervals provided in Table 8 indicate that the group receiving dental treatment was statistically superior to the control group in terms of calculus reduction.

[0193] Table 9: Week 4 Analysis Results of Covariance Results of Volpe-Manhold Index Estimated Standard Deviation T-value Pr>|t| α Lower Limit Upper Limit Group A minus Group C 8.7642 0.8490 10.32 <.0001 0.05 7.0370 10.4914 Group A minus Group B 8.7942 0.8854 9.93 <.0001 0.05 6.9929 10.5955 Group B minus Group C 0.0300 1.0287 0.03 0.9769 0.05 -2.0629 2.1229 Safety (Week 2 and Week 4) Oral soft and hard tissue examinations (OSHT) were performed at baseline, week 2, and week 4. As shown in Table 5, except for 4 participants (#1019, #1024, #1032, #1013), all findings at weeks 2 and 4 were continuations of the prior symptoms noted at baseline.

[0194] Example 7: Results Summary The results from the study indicated that the participants tolerated the use of the disclosed enzyme formulation well.

[0195] During the 4-week study, participants showed clinically significant and statistically significant reductions in calculus (Figure 4). Furthermore, participants in the active treatment group gave more favorable responses to how clean their teeth felt. Compared to the control group, 75% of group B (enzyme formulation) and 67% of group C (enzyme formulation with tray) gave positive feedback, while only 50% of participants in the control group gave positive feedback (data not shown). In addition, groups B and C reported that their teeth felt cleaner, smoother, and less gritty (Figure 5). Instructions for Use, Pages 28 / 35, 31, CN 121463944 A

[0196] Example 8: Analysis of the Composition and Structure of Dental Plaque / Charcoal. Charcoal collected from teeth using a metal alloy dental probe was placed in 0.5 mL of water in a 1.5 mL microcentrifuge tube. The charcoal was crushed using a Teflon pestle mounted on the microcentrifuge tube. The contents were centrifuged, the supernatant was aspirated and resuspended in 1 mL of water, and 100 μL aliquots were taken and placed in one or more microcentrifuge tubes. The contents of each tube were centrifuged, the supernatant was aspirated and then resuspended in 300 μL of water in a tube containing one of the following: No added substances (water control), trypsin, chymotrypsin, DNase 1, nuclease "Genius nuclease". The contents of each tube were mixed and incubated at approximately 37°C for 30 minutes. The contents were centrifuged, the supernatant was removed, and the presence and amount of protein, DNA, and calcium were analyzed. The original quantification was multiplied by a dilution factor (e.g., 1:3 for calcium, 1:5 for DNA, or 1:5 for protein) to obtain the total amount of protein, DNA, or calcium isolated from the sample. Table 11 shows the results obtained.The results shown in Table 11 indicate that chymotrypsin and DNase 1 are more effective than trypsin or other nucleases in extracting proteins, DNA, or calcium from stones.

[0197] Table 11: Percentage of observed maximum product yield Protein (control) DNA (control) Calcium (control) Control 100 100 100 Trypsin 397 691.7 241.6 Chymotrypsin 7225.2 1125 550 DNA enzyme 1 3137.8 900 258.3 Nuclease 557.4 300 50 “Genius nuclease” 173.8 0 25 Example 9: Human Clinical Study Method As a parallel-group, examiner-blinded, randomized, triple-treatment clinical trial, a proof-of-principle human clinical study was conducted to evaluate the safety and efficacy of a novel enzyme formulation (i.e., Tartarase) in removing existing calculus deposits within one month, which were measured on the lingual surfaces of six lower anterior teeth using the Volpe-Manhold index (V-MI). Secondary objectives included a safety assessment evaluated by examining gingival tissue (free and attached), hard and soft palate, oropharynx, buccal mucosa, tongue, floor of mouth, labial mucosa, buccal / labial mucosal folds, lips, and perioral region. Additionally, a questionnaire assessing oral cleanliness using a five-point subjective scale (1 = least clean and 5 = cleanest) was included as an exploratory endpoint. Safety assessments and oral examinations were performed at all visits. Forty participants consented to enrollment, with 20 randomized to the control group (Crest Cavity Protection) and 20 to the Tartarase treatment group.

[0198] This study was approved by the USIRB (USIRB2022SRI / 10) in accordance with ICH Guideline E6 and the US Food and Drug Administration, and conducted by Salus Research, Inc. (an American Dental Association (ADA) Qualified Independent Research Site). The study product was fluoride-free, and the IRB required all participants to brush their teeth twice daily with fluoride toothpaste.

[0199] Adult subjects with six (6) mandibular anterior teeth were recruited from the Salus Research database as rapid tartar builders, as described in the specification 29 / 35 pages 32 CN 121463944 A, who had at least 9 mm of tartar measured on their mandibular anterior six teeth, which was evaluated using V-MI (dental cleaning completed between 2 and 6 months prior to the start of the study).Subjects who did not brush their teeth regularly, used chlorhexidine mouthwash, or required antibiotic prophylaxis before dental procedures were excluded. Subjects were withdrawn from the study if they did not follow the product instructions or used any oral hygiene product other than the designated study product. Flossing, electric toothbrushes, and mouthwash were prohibited.

[0200] Participants were evaluated at the initial visit to ensure at least 9 mm of tartar on the lingual surfaces of the six mandibular anterior teeth, and eligible subjects were assessed for demographics, medical history, and concomitant medications. Forty eligible subjects were randomly assigned to one of three study groups using a randomization protocol developed and maintained by an independent statistician. Subjects were stratified by baseline lingual V-MI tartar score and sex. Half of the test subjects (n=20) were randomized to the control group, and 10 were assigned to each Tartarase group (Tartarase Brush only and Tartarase Brush + tray). All subjects underwent their first use under supervision at the study site, followed by unsupervised use during the 4-week test period. For each subject, evaluation data were collected at baseline, 2, and 4 weeks (Table 12). All test subjects used the same ADA reference soft manual toothbrush and brushed twice daily with control toothpaste Crest® Cavity Protection Cool Mint Gel (0.243% sodium fluoride). The test groups were assigned as follows: 1. Control (20 subjects): Brushed twice daily with an ADA toothbrush and Crest toothpaste for two minutes each time.

[0201] 2. Tartarase Brush (10 subjects): Brushed twice daily with Tartarase and twice daily with Crest toothpaste.

[0202] 3. Tartarase Tray (10 subjects): Custom-made trays were made for all Tartarase tray subjects. Test subjects brushed with Tartarase for 1 minute, then applied Tartarase using the custom tray (worn once daily for 30 minutes). The procedure was then repeated with another 1 minute of Tartarase brushing. The Tartarase brush / tray / brushing was performed once daily. Participants also brushed their teeth twice daily with Crest.

[0203] Table 12: Baseline characteristics, including mean Volpe-Manhold index (V-MI) for different treatment groups, demographic data for different treatment groups, and those with normal brushing habits in different treatment groups. Instructions for Use 30 / 35 pages 33 CN 121463944 A

[0204] Tartarase formulation: This formulation was prepared in two batches, each sufficient for 20 participants to brush at 2.0 ml / day for 14 days.Cetearyl alcohol polyether-25 (0.23%), glycerol (13.6%), xanthan gum (0.28%), sorbitol (4.4%), and hydrated silica (11%). DNase 1 (197,326 Kunitz units / ml) and chymotrypsin (3,333 units / ml). These enzymes were obtained from Worthington Biochemicals.

[0205] For this 1-month study, the test product was formulated using twice the level shown to be effective per unit volume in previous preclinical studies using canine calculus.

[0206] Efficacy evaluation and statistical analysis were determined by changes in calculus within the treatment group (longitudinal analysis) and between groups compared to the control group after 4 weeks of treatment. Additionally, the efficacy of the Tartarase treatment group was determined by prevention of calculus accumulation, which was assessed by no significant increase in calculus score compared to baseline. The primary outcome was calculus abundance using the Volpe-Manhold index, and all other variables were considered minor. Measurements were taken on the lingual surfaces of the six mandibular anterior teeth. The calculus scores of this index were summed to provide a total score for each oral cavity at each clinical examination. The principal time point was at the end of the trial, four weeks after product use.

[0207] Data from all subjects who completed the final evaluation were used in the analysis. Data for each scoring index were also analyzed using analysis of covariance with baseline data as covariates. Covariates (baseline data) were included in the statistical model to improve the accuracy of determining the effect of the test product on the scores. Adjusted means generated by this procedure compensated for any differences between treatment groups present in the baseline data. This reduced variability and increased power, and also adjusted for baseline imbalances due to subject attrition. Longitudinal (i.e., within-treatment) comparisons of the V-MI mean were made using a one-sample t-test based on the change from baseline to the final examination. All comparisons were performed using two-tailed tests at an overall significance level of 0.05.

[0208] Safety Assessment Oral examinations were performed at all visits, including the gingiva (free and attached), hard and soft palate, oropharynx, buccal mucosa, tongue, floor of mouth, labial mucosa, buccal / labial mucosal folds, lips, and perioral region. Additionally, subjects were asked about any adverse events (AEs) since their previous visit. AEs were categorized as serious or non-serious based on severity, whether expected or unexpected, and their possible relationship to the test product. All AEs (examiner and self-report) were assessed at subsequent visits to determine if they had been resolved.

[0209] Results An overview of the daily brushing schedule for the study group is shown in Figure 6. Forty (40) subjects were randomized and thirty-seven (37) completed the study. One patient refused to comply with the study procedures and was removed from the study; two patients withdrew their consent forms.For the randomized subjects, the sex distribution was 22 women and 18 men. The mean age was 50.4 years, with a minimum of 23 years and a maximum of 74 years. Caucasians comprised 33 of the 40 subjects (82.5%), and none of the patients identified as Hispanic or Latino. Baseline calculus scores were similar across all treatments. Subjects reported similar daily oral hygiene routines (twice daily).

[0210] Efficacy: In the 4-week study, both treatments with Tartarase reduced calculus. Specifically, the Tartarase brushing group alone removed 40.0% of calculus, and the Tartarase brushing + tray group removed 38.1%. Longitudinal within-group analysis showed statistically significant calculus reduction in both Tartarase groups over the 4-week study (p<0.001) and was statistically different from the Crest control group (Table 13). Results were similar in both Tartarase treatment groups, and all 17 assigned to the experimental product showed calculus reduction (Figure 7). In contrast, during the 4-week study, the Crest control group showed a statistically significant increase in calculus of 12.2% (p<0.001). Furthermore, the Crest control group also showed increased calculus deposition in test subjects (Figure 7). No significant changes were observed in either test group at the 2-week examination assessment.

[0211] Table 13: Mean baseline and 4-week V-MI measurements and percentage changes and directions of V-MI in different treatment groups. Compared to the control group, participants in the Tartarase treatment group reported more favorable responses regarding how clean their teeth felt. 75% of those brushing with Tartarase only and 67% of those brushing with Tararase + tray self-reported a positive rating of “4” or “5” (5 = cleanest) (Figure 8). The control group reported 50% positive ratings for both “4” and “5”. Test subjects were given the opportunity to provide their overall impressions of the oral cleanliness of their assigned Tartarase product, including: 1. “I can feel every tooth in my mouth, and they all feel smooth.” 2. “I can feel my individual teeth are better, and my lower inner teeth feel cleaner.” 3. “I feel like my mouth stays clean and fresh all day. My breath smells better.” Safety Issues No safety issues were noted with Tartarase use, and there were no serious adverse events (AEs) or any sarcastic or inflammatory responses (SAEs). Tartarase was well tolerated. Based on oral examination, there were 5 AEs (4 AEs were attributed to toothbrush abrasion and one was mild inflammation of the anterior papillae of the tongue).In total, there was 1 adverse event (AE) in the control group, 3 AEs in the Tartarase brushing group, and 1 AE in the Tartarase tray group (Table 14). No changes in oral hard tissues were observed during the 4-week trial period. Three test subjects self-reported AEs, of which 2 reported gingival or lip sensitivity (Tartarase tray group) and 1 experienced tongue burning (Tartarase brushing group). All AEs (inspector observation and self-report) were resolved within a 5-day reassessment period (Table 14).

[0212] Table 14: Overview of Adverse Events 32 / 35 pages 35 CN 121463944 A Overview of Example 9 After 4 weeks, Tartarase significantly reduced tartar, with a reduction of approximately 40% in both Tartarase test groups, while the Crest control group showed an increase of 12% in tartar deposits. Furthermore, after 4 weeks of unsupervised daily use, tartar was reduced in every Tartarase test subject. Not wanting to be bound by theory, the results of this study support the theory that DNA and proteins together provide structural support for tartar, and that enzymes targeting DNA and denatured proteins are particularly effective in breaking down the structure of tartar, thereby reversing tartar buildup. Equally important, the results showed no evidence of further tartar buildup, indicating that the Tartarase formulation effectively prevents tartar formation after cleaning. Tartarase test subjects showed approximately a 40% reduction in tartar over 4 weeks, while the control group experienced a 12% increase. Consideration should be given to creating custom trays for application.

[0213] Since the active ingredient in Tartarase is an enzyme, it is important to consider the overall characteristics of the enzyme. Enzymes are protein catalysts. They promote normally occurring chemical reactions to occur at an enhanced rate. Additionally, they allow reactions to occur in both forward and reverse directions. Therefore, for these types of enzymes, accumulated products inhibit the enzyme from catalyzing its forward reaction. This may explain why the Tartarase tray group did not outperform the Tartarase brushing group. Furthermore, in vitro studies have found that enzymes act extremely rapidly, with reactions completed in <5 minutes, indicating that the 30-minute incubation time in the tray group did not provide an advantage.

[0214] Preclinical studies have supported the importance of dual-enzyme formulations. It is hypothesized that the only way to attack calculus is on its outer two-dimensional surface. The model of calculus structure has a calcified complex of a basic biopolymer. If an enzyme is specific to only one complex biopolymer, it cannot proceed further once the target biopolymer has been consumed, as the remaining target is masked by biopolymers that are not the target of that single enzyme. Therefore, the combined use of enzymes allows for a progressive mechanism that systematically peels calculus from its outermost surface, eventually reaching the enamel.

[0215] Clinical studies have demonstrated the ability to reduce calculus.During the 4-week trial period, the tested Tartarase toothpaste showed significant tartar removal in test subjects who were known tartar builders and had cleaned their teeth between 2 and 6 months prior to the study. This trial suggests that the Tartarase formulation has the potential to reduce tartar when used in daily routine oral hygiene.

[0216] This experiment was designed to evaluate the safety and efficacy of a novel enzyme formulation (i.e., Tartarase) in removing existing tartar deposits within one month, measured using the Volpe-Manhold index (V-MI) on the lingual surfaces of the six lower anterior teeth. The test formulation, containing a large excess of active enzyme in a common mixture of inactive ingredients, was compared with Crest Cavity Protection as a control. A total of 40 randomized participants began the study, with 20 assigned to the control group and 20 to the Tartarase group (one group brushed with Tartarase twice daily, and the other group brushed with Tartarase and wore a Tartarase-filled dental tray for 30 minutes, followed by brushing with Tartarase again). Results showed a 12% increase in tartar in the Crest control group compared to a 40% reduction in tartar in the Tartarase group.

[0217] Table 15: Sequence Specification Pages 34 / 35 37 CN 121463944 A Specification Pages 35 / 35 38 CN 121463944 A Figure 1 Specification Figure 1 / 9 Pages 39 CN 121463944 A Figure 2 Specification Figure 2 / 9 Pages 40 CN 121463944 A Figure 2 Continued Specification Figure 3 / 9 Pages 41 CN 121463944 A Figure 3 Specification Figure 4 / 9 Pages 42 CN 121463944 A Figure 4 Specification Figure 5 / 9 Pages 43 CN 121463944 A Figure 5 Specification Figure 6 / 9 Pages 44 CN 121463944 A Figure 6 Specification Figure 7 / 9 Pages 45 CN 121463944 A Figure 7 Specification Figure 8 / 9 Pages 46 CN 121463944 A Figure 8 Specification Figure 9 / 9 Page 47 CN 121463944 A.

Claims

1. A dental composition comprising: a. DNA enzymes and / or RNA enzymes; b. Chymotrypsin or its functional variants or derivatives; and c. Orally acceptable additives, carriers or excipients, or any combination thereof.

2. The dental composition according to claim 1, wherein the composition does not contain β-galactosidase.

3. The dental composition according to any one of claims 1 or 2, wherein the DNase is present in an amount of about 50,000 to about 250,000, or about 100,000 to about 200,000, or about 150,000 to about 200,000, or 150,000, or 160,000, or 170,000, or 180,000, or 185,000, or 190,000, or 200,000 Kunitz units / mL.

4. The dental composition according to any one of claims 1-3, wherein the DNase is DNase I or a functional variant or derivative thereof.

5. The dental composition according to any one of claims 1-4, wherein chymotrypsin or a functional variant or derivative thereof is present in an amount of about 100 to about 5,000, or about 500 to about 4,000, or about 1,000 to about 3,000, or 1,500, or 1,600, or 1,700, or 1,800, or 1,900, or 2,000, or 2,100, or 2,200, or 2,300, or 2,400, or 2,500, or 2,600, or 2,700, or 2,800, or 2,900 or 3,000 units / mL based on the hydrolysis rate of the chromogenic substrate.

6. The dental composition of claim 1, wherein the orally acceptable additive is a thickener and / or gelling agent selected from gellan gum (low-acyl or high-acyl), glycerin, silica, guar gum, xanthan gum, polyethylene glycol, polyvinylpyrrolidone and its copolymers, polylactic acid, polyglycolic acid, long-chain fatty acid alcohols, cellulose-based polymers, acrylate polymers and any combination thereof.

7. The dental composition of claim 1, wherein the orally acceptable carrier is selected from ethanol, isopropanol, glycerol, or sorbitol.

8. The dental composition of claim 1, further comprising a surfactant selected from cetearyl alcohol polyether or stearyl alcohol polyether.

9. The dental composition of claim 1, wherein the composition comprises: a. DNA enzyme I or its functional variants or derivatives a. Chymotrypsin or its functional variants or derivatives; and one or more of the following, c. 10%-20% glycerin, d. 0.000001%-0.00001% cetearyl alcohol polyether-25, e. 0.1%-0.5% xanthan gum, f. 1%-10% sorbitol, and g.5-25% silicon dioxide.

10. The dental composition according to claim 9, further comprising water.

11. An oral hygiene device comprising the composition according to any one of claims 1-10, wherein the composition is combined with a dental tray, capsule applicator, oral cleaning stick, or dental floss.

12. Use of the composition or device according to any one of claims 1-11 for the removal of dental calculus in a subject in need of it.

13. Use of the composition according to claim 12, wherein the subject is a mammal.

14. Use of the composition according to claim 12, wherein the subject is a human.

15. A method for reducing or removing dental calculus in a subject in need of it, said method comprising contacting a tooth surface with an effective amount of a composition comprising: a. DNA enzyme I or its functional variants or derivatives, and b. Chymotrypsin or its functional variants or derivatives.

16. The method of claim 15, wherein the composition does not contain β-galactosidase.

17. The method of claim 15, wherein the composition further comprises an orally acceptable additive, carrier, or excipient, or a combination thereof.

18. The method according to any one of claims 15-17, wherein the composition comprises a paste or liquid, and contact with the tooth surface comprises applying the composition using a brush, a tray, a mouthwash, or any combination thereof.

19. The method of claim 18, wherein the method comprises applying the medication at least once a day, at least twice a day, or at least three times a day for a period of at least one week.

20. A method for reducing or removing dental calculus in a subject in need of it, the method comprising contacting a tooth surface with an effective amount of the composition of any one of claims 1-10.

21. The method according to any one of claims 15-20, wherein the subject is a mammal.

22. The method of claim 21, wherein the subject is a dog, horse, cat, or primate.

23. The method of claim 21, wherein the subject is a human.

24. A kit comprising: a. The composition according to any one of claims 1-10; b. Instructions for use.

25. The kit of claim 24, further comprising at least one applicator selected from toothbrushes, oral cleaning sticks, dental floss, and dental trays.